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INTRODUCTION 
 
Acute kidney injury (AKI) is a protean syndrome of varied severity. It is 
characterized by a rapid (hours to weeks) decline in the glomerular filtration rate 
(GFR) and retention of nitrogenous waste products such as blood urea nitrogen 
(BUN) and creatinine1,2. In recent years, it has been recognized that the time – 
honored term Acute Renal Failure fails to adequately describe what is a dynamic 
process extending across initiation, maintenance and recovery phases, each of 
which may be of variable duration and severity. The term Acute Renal Failure 
suggests that the syndrome is dichotomous and places an undue emphasis on 
whether or not renal function has overtly failed. This believes the now well-
established fact that even mild decrements in glomerular filtration may be 
associated with adverse clinical outcomes3,4. The alternative proposed term acute 
kidney injury has much to recommend it, perhaps better captures the diverse nature 
of this syndrome and has entered into widespread clinical use. 
AKI may occur in someone either with previously normal renal function or 
as an acute and anticipated deterioration in function in the setting of previously 
established chronic kidney disease. The etiology and outcomes of AKI is heavily 
influenced by the circumstances in which it occurs, such as whether it develops in 
the community or in the hospital. It is similarly important to distinguish whether the 
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kidney injures occurs as an isolated process, which is more common in community 
acquired AKI, or if it occurs as part as a more extensive multiorgan syndrome5.       
In 2004, Acute Dialysis Quality Initiative (ADQI) group, International 
Society of Nephrology (ISN), National Kidney Foundation (NKF) and American 
Society of Nephrology (ASN) met and proposed the term ‘Acute Kidney Injury.  
AKI generally defined as: 
 ‘an abrupt and sustained decrease in kidney function’ 
Acute Dialysis Quality Improvement Initiative (ADQI) has proposed a new 
definition of AKI, that has been widely endorsed and is increasingly being used in 
keeping with the spectrum of changes seen in AKI,  the diagnostic classification 
scheme was developed,  this scheme is referred to by the acronym RIFLE, and 
includes three levels of renal dysfunction of increasing severity, namely. Risk of 
renal dysfunction, injury to the kidney and failure of kidney functions, and two 
outcome categories: Loss of function. And End stage kidney disease. Renal 
dysfunction is defined in terms of a rise in creatinine or a reduction in urine output, 
the more severe of the two criteria being selected. When achieved designation 
results from urine output criteria a subscript "o" is added e.g. RIFLE-Fo. Similarly, 
a subscript of "c" is used to denote the presence of preexisting renal disease6. 
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RIFLE classification scheme for Acute Kidney Injury6 
                      GFR criteria                Urine output criteria 
risk Increased Serum Creatinine  x  1.5 
GFR decrease >25% 
UO<.5 ml/ kg /h 
X 6hr 
injury Increased Serum Creatinine x 2 or 
GFR decrease > 50% 
UO< .5 ml/ kg / h  
X 12 hr 
Failure Increased Serum Creatinine x 3 
GFR decrease > 75% 
            Or 
Serum Creatinine < 4 mg / dl 
Acute rise >.5 mg/dl 
UO < .3 ml/ kg / h 
X 24 hr or 
Anuria x 12 hrs 
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Loss        Persistent AKI = complete loss of  
Kidney function > 4 weeks 
ESKD End Stage Kidney Disease  
( > 3months) Hi
gh
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RIFLE is also useful at predicting outcome data including recovery of renal 
function, length of hospital stay, renal replacement requirement and in-hospital 
mortality. 
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 In 2004, Acute Kidney Injury Network (AKIN) formed .AKIN proposed a 
diagnostic criteria for the definition AKI:  
 “An abrupt (within 48 hours) reduction in kidney function currently defined 
as an absolute increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 
26.4 µmol/l), a percentage increase in serum creatinine of more than or equal to 
50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of 
less than 0.5 ml/kg per hour for more than six hours).”  
Data has emerged recently that suggests smaller increases in Serum 
Creatinine  than those considered in RIFLE criteria may be associated with adverse 
outcomes.  So AKIN proposed a new classification/staging system. 
Classification/staging system for acute kidney injury 
Stage Serum creatinine criteria Urine output criteria 
 
1 
Increase in Serum Creatinine of > 0.3 
mg/dl (>26.4 µmol/l) or to > 150% to 
200% (1.5 to 2 fold) from baseline 
Less than 0.5 ml/kg per hr for 
more than 6 hrs 
 
2 
Increase in Serum Creatinine to more 
than 200% to 300%  (> 2 – 3 fold) 
from baseline 
Less than 0.5 ml/kg per hr for 
more than 12 hrs 
 
3 
Increase in Serum Creatinine to more 
than 300% (>3 fold) from baseline or  
Serum Creatinine >4.0 mg/dl [>354 
µmol/l] with an acute increase of at 
least 0.5 mg/dl [44 µ/l] 
Less than 0.3 ml/kg per hr or 
anuria 12 hrs 
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A major challenge in the investigation and management of AKI is timely 
recognition of the syndrome. It remains difficult to easily and reliably measure 
rapid changes in the GFR. Although the severity in decline in GFR correlates with 
the onset of oliguria, the latter is insensitive marker of the syndrome because many 
subjects with severe renal failure remain non oliguric. In AKI, there is a poor 
agreement between serum creatinine and GFR, at least until a serum creatinine 
steady state is reached and even then , the absolute rise in serum creatinine must 
take into account differences in creatinine generation rates7. 
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AIMS  AND OBJECTIVES 
 
1) To study about the etiological profile of  acute kidney injury 
2) To apply the RIFLE criteria in  acute kidney injury patients admitted 
to the medical wards and to confirm the significance 
3) To study about the prognosis and outcomes of acute kidney injury 
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REVIEW OF LITERATURE 
Acute Kidney Injury of course must have followed on many major traumas 
and tragedies throughout the history, but had not been noted until the 20th century. 
The first  report of fatal Acute Kidney Injury is accreditated to Hackradt, a German 
pathologist in 1917 and was based on soldiers who sustained severe traumatic 
injuries.  The concept of Acute Kidney Injury on a previously normal kidney was 
better understood during and after second worldwar.  In 1941 Bywaters and Beall 
described ‘crush kidney’ syndrome in victims of London Blitz9.  Subsequent studies 
showed acute, potentially reversible failure of renal function, associated with 
histological findings of acute tubular necrosis, could also due to other causes such 
as mismatched blood transfusion abortion, cardiovascular collapse, sepsis and a 
variety of nephrotoxic substances. 
 In recent years, new causes which have been reported include Hantaan virus, 
ingestion of raw fish gallbladder, quinine hypersensitivity, chewing match heads, 
Ectasy, HIV infection, physical torture, inhalation of mycotoxins, gelatin infusion, 
and herbal medicine8. 
Nash et al, 200261 using same AKI defining criteria at a different institution, 
reported frequency of AKI in hospitalised pts had increased to 7.2%.In-hospital 
mortality rate was 19.4%. Major causes were decreased renal perfusion (39%), 
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nephrotoxin administration (16%), contrast administration (11%), major surgery 
(9%) 
Liano et al, 1996 Madrid62 did study in 13 centres covering 4.2 million 
people 748 episodes of AKI during 200,464 admissions (0.37%). Overall incidence 
of AKI was 209 cases per million population. Frequent causes: ATN (45%), 
prerenal (21%), acute-on-chronic kidney disease (12.7%), obstructive (10%). 
Mortality was much higher in AKI pts (45%) to other pts admitted (5.4%) 
Ostermann M, Chang RW: CCM 200763 showed AKI is an independent 
risk factor for death. Patients don’t just die with AKI they die because of AKI. 
They detected the following: 
• RIFLE class F have a mortality of 57% 
• RIFLE class I 45% 
• RIFLE class R 21 % 
Compared to 8.4% of patients without AKI 
The aetiology of AKI varies from place to place within the country.  Acute 
diarrhoeal disease is the commonest cause of AKI.  The incidence of snake bite 
induced AKI is higher in North India, while leptospirosis AKI commonly 
encountered in Kerala and Chennai.  Malarial AKI is common in Eastern India.   
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INCIDENCE                                   
AKI complicates approximately 5-7% of hospital admissions10 and up to 
30% of admissions to intensive care units11.  Retention of nitrogenous waste 
products, oliguria (urine output <400 mL/d contributing to extracellular fluid 
overload), and electrolyte and acid base abnormalities are frequent clinical features. 
AKI is usually asymptomatic and diagnosed when biochemical monitoring of 
hospitalized patients reveals a new increase in blood urea and serum creatinine 
concentrations. 
For purposes of diagnosis and management, AKI has been divided into three 
categories. 
              1. Disease characterized by renal hypoperfusion in which the integrity of 
renal  parenchymal tissue is preserved ( prerenal states) (~55%); 
               2. Diseases involving renal parenchymal tissue (intrarenal AKI or intrinsic 
AKI(~40%); and 
               3. Diseases associated with acute obstruction of urinary tract (post renal or 
obstructive AKI) (~5%). 
AKI is often considered to be reversible, although a return to baseline serum 
creatinine concentrations postinjury might not be sufficiently sensitive to detect 
clinically significant irreversible damage that may ultimately contribute to chronic 
kidney disease. AKI is associated and significant in-hospital morbidity and 
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mortality, the latter in the range of 30-60%, depending on the clinical setting and 
presence or absence of nonrenal organ system failure. 
CLASSIFICATION AND MAJOR CAUSES OF ACUTE KIDNEY 
INJURY64: 
PRERENAL AKI 
1) Hypovolemia 
a)  Increased extracellular fluid losses: hemorrhage 
b)  Gastrointestinal fluid loss: vomiting, diarrhea, enterocutaneous fistula 
c)    Renal fluid loss: diuretics, osmotic dieresis, hypoadrenalism,  
  nephrogenic diabetes insipidus 
  d)  Extravascular sequestration: burns, pancreatitis, severe  
   hypoalbuminemia (hypoproteinemia) 
e)  Decreased intake: dehydration, altered mental status 
2) Altered renal hemodynamics resulting in hypoperfusion 
a)  Low cardiac output state: diseases of the myocardium, valves, and 
pericardium (including tamponade); pulmonary hypertension or 
massive pulmonary embolism leading to right and left heart failure; 
impaired venous return (eg. Abdominal compartment syndrome or 
positive pressure ventilation)  
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b)  Systemic vasodilation: sepsis, anti-hypertensives, afterload reducers, 
anaphylaxis 
c)  Renal vasoconstriction: hypercalcemia, catecholamines, calcineurin 
inhibitors, amphotericin B 
d)    Impairment of renal autoregulatory responses: cyclooxygenase 
inhibitors   (NSAIDs), ACE Inhibitors15, or AT II receptor blockers 
e)     Hepatorenal syndrome 
INTRINSIC AKI 
1)   Renovascular obstruction (bilateral or unilateral in the setting of one kidney) 
a)    Renal artery obstruction: atherosclerotic plaque, thrombosis, 
embolism,   dissecting aneurysm, large vessel vasculitis 
b)    Renal vein obstruction: thrombosis or compression 
2) Diseases of the glomeruli or vasculature 
a)     Glomerulonephritis or vasculitis 
b)    Other: thrombotic microangiopathy, malignant hypertension, collagen 
vascular disease (systemic lupus erythematosus, scleroderma), DIC, 
preeclampsia 
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3) Acute tubular necrosis 
a)  Ischemia: causes are the same as for prerenal AKI, but generally the  
insult is more severe and/or more prolonged 
b)     Infection, with or without sepsis syndrome 
c)    Toxins: 1. Exogenous: radiocontrast, calcineurin inhibitors, antibiotics 
(eg. Amphotericin B), ethylene glycol,  
2. Endogenous: rhabdomyolysis, hemolysis 
4) Interstitial nephritis 
a)    Allergic: antibiotics (betalactams, sulfonamides, quinolones, rifampin),   
NSAIDs, diuretics, other drugs 
b)     Infection: pyelonephritis (if bilateral) 
c)     Infiltration: lymphoma, leukemia, sarcoidosis 
d)  Inflammatory, non-vascular: Sjogren’s syndrome, tubulointerstitial    
nephritis with uveitis 
5) Intratubular obstruction 
a)  Endogenous: myeloma proteins, uric acid (tumor lysis syndrome),  
systemic oxalalosis 
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b)    Exogenous: acyclovir, gancyclovir, methotrexate, indinavir 
 POSTRENAL AKI (obstruction) 
1)   Ureteric (bilateral or unilateral in the case of one kidney): calculi,  
blood clots, sloughed papillae, cancer, external compression (eg. 
Retroperitoneal fibrosis) 
2)   Bladder neck: neurogenic bladder, prostatic hypertrophy, calculi, blood 
clots, cancer. 
ETIOLOGY AND PATHOPHYSIOLOGY 
PRERENAL AKI                                
The most common form of AKI is prerenal AKI, which occurs in the setting 
of renal hypoperfusion. Prerenal AKI is generally reversible when perfusion 
pressure is restored.  By definition, renal parenchymal tissue is not damaged.  More 
severe or prolonged hypoperfusion may lead to ischemic injury, often termed acute 
tubular necrosis, or ATN. Thus prerenal AKI and ischemic ATN fall along a 
spectrum of manifestations of renal hypoperfusion.  Prerenal AKI complicate any 
disease that induces hypovolemia, low cardiac output, systemic vasodilatation, or 
selective intrarenal vasoconstriction.   
Hypovolemia leads to a fall in mean systemic arterial pressure, which is 
detected as reduced stretch by arterial (e.g., carotid sinus) and cardiac 
baroreceptors.  In turn, this triggers a coordinated series of neurohormonal 
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responses that aim to restore blood volume and arterial pressure.  These include 
activation of the sympathetic nervous system and renin-angiotensin-aldosterone 
system, as well as release of arginine vasopressin12. Relatively “nonessential” 
vascular beds (such as the musculocutaneous  and splanchnic circulations) undergo 
vasoconstriction in an attempt to preserve cardiac and cerebal perfusion pressure.  
In additional salt loss through sweat glands is inhibited, and thirst and salt appetite 
are stimulated.  Renal salt and water retention also occur. 
In states of mild hypoperfusion, glomerular perfusion and the filtration 
fraction are preserved through several compensatory mechanisms.  In response to 
the reduction in perfusion pressure, stretch receptors in afferent arterioles trigger 
afferent arteriolar vasodilatation through a local myogenic reflex (autoregulation).  
Angiotensin II increases biosynthesis of vasodilator prostaglandins (e.g., 
prostaglandin E2 and prostacyclin), also resulting in afferent arteriolar vasodilation.  
In addition, angiotensin II induces preferential constriction of efferent arterioles.   
As a result, the fraction of plasma flowing through glomerular capillaries that is 
filtered is increased (filtration fraction), intra glamerular pressure is maintained, and 
GFR is preserved.  With more severe hypoperfusion, these compensatory responses 
are overwhelmed and GFR falls, leading to prerenal AKI13,14. 
 Autoregulatory dilatation of afferent arterioles allows for maintenance of 
GFR despite systemic hypotension; however, when hypotension is severe or 
prolonged, these autoregulatory mechanisms fail, resulting in a precipitous decline 
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in GFR.  Lesser degrees of hypotension may provoke prerenal AKI in those at risk: 
the elderly and patients with diseases that affect the integrity of afferent arterioles 
(e.g., hypertensive nephrosclerosis, diabetic vasculopathy and other forms of 
occlusive including atherosclerotic  renovascular disease).  In addition, drugs that 
interfere with adaptive responses to hypoperfusion may convert compensated renal 
hypoperfusion into overt prerenal AKI or ATN.  Pharmacologic inhibitors of renal 
prostaglandin biosynthesis (nonsteridal anti-inflammatory drugs16 (NSAIDs) or 
angiotensin-converting enzyme inhibitors15 (ACEI) and angiotensin II receptor 
blockers (ARBs) are major culprits.  While NSAIDs do not compromise GFR in 
healthy individuals, these medications may perecipitate prerenal AKI in patients 
with volume depletion or in those with chronic kidney disease (in whom GFR is 
maintained, in part, through prostaglandin mediated hyperfiltration by the 
remaining fuctional nephrons).  ACE inhibitors should be used with special care in 
patients with bilateral renal anery stenosis or unilateral stenosis in a solitary 
functioning kidney.  In these settings, glomerular perfusion and filtration may be 
exquisitely dependent on the actions of angiotensin II. Angiotensin II preserves 
GFR in these circumstances by raising systemic arterial pressure and by triggering 
selective constriction of efferent arterioles.  ACE inhibitors and ARBs blunt these 
responses and can precipitate AKI. 
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INTRINSIC AKI 
Intrinsic cause of AKI can be conceptually divided based on the predominant 
compartment of the kidney that is affected:  
                                 (1) Ischemic or nephrotoxic tubular injury  
                                 (2) Tubulointerstitial diseases  
                                  (3) Diseases of the renal microcirculation and glomeruli, and  
                                  (4) Diseases of larger renal vessels.   
Ischemia and nephrotoxins classically induce acute tubular injury.  Although 
many patients with ischemic or nephrotoxic  AKI do not have morphologic 
evidence of cellular necrosis, this disease is often referred to as acute tubular 
necrosis, or ATN.  More recently, because of the important role of sublethal injury 
to tubular epithelial and other renal cells (e.g., endothelial cells) in the pathogenesis 
of this syndrome, the term acute kidney injury (AKI)has been proposed. 
ETILOLOGY AND PATHOPHYSIOLOGY OF ISCHEMIC ATN 
Prerenal AKI and ischemic ATN are part of a spectrum of manifestations of 
renal hypoperfusion17,  In its most extreme form, ischemia leads  to bilateral renal 
cortical necrosis and irreversible renal failure.  ATN differs from prerenal AKI in 
that the renal tubular epithelial cells are injured in the latter. ATN occurs most 
frequently in patients undergoing major cardiovascular surgery of suffering severe 
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trauma, hemorrhage, sepsis, and/or volume depletion18,19,20.  Patients with other risk 
factors for AKI (e.g., exposure to nephrotoxins or preexisting chronic kidney 
disease) are at increased risk for ATN.  Recovery typically takes 1-2 weeks after 
normalization of renal perfusion, as it requires repair and regeneration of renal cells. 
The course of ischemic ATN is typically characterized by four phases: 
initiation, extension, maintenance, and recovery.  These phases are often preceded 
by a period of prerenal azotemia. 
            During the inititation phase (lasting hours to days), GFR declines because  
(1) glomerular ultrafiltration pressure is reduced as renal blood flow falls, (2) the 
flow of filtrate within tubules is obstructed by casts comprised of shed epithelial 
cells and necrotic debris, and (3) there is backleak of glomerular filtrate through 
injured tubular epithelium.  Ischemic injury is most prominent in the S3 segment of 
the proximal tubule and the medullary portion of the thick ascending limb of the 
loop of Henle.  These segments of the tubule are particularly sensitive to ischemia 
because of high rates of active (ATP-dependent) solute transport and location in the 
outer medulla, where the partial pressure oxygen is low, even under basal 
conditions, Cellular ischemia results in  ATP depletion, inhibition of  active sodium 
transport, cytoskeletal disruption, loss of cell polarity, cell-cell and cell-matrix 
attachment, and  Oxygen free- radical formation26.  Renal injury may be limited by 
restoration of renal blood flow during this period.  If severe, cell injury results in 
apoptosis or necrosis. 
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The extension phase follows the initiation phase and is characterized by 
continued ischemic injury and inflammation.  It has been proposed that endothelial 
damage (resulting in vascular congestion) contributes to both of these processes.  
During the maintenance phase (typically 1-2 weeks), GFR stabilizes at its nadir 
(typically 5-10 mL/min), urine output is lowest, and uremic complications may 
arise. Its not clear why the GFR remains low during this phase, despite correction of 
systemic hemodynamics. Proposed mechanisms include persistent intrarenal 
vasoconstriction and medullary ischemia trigger dysregulated release of vasoactive 
mediators from injured endothelial cells, congestion of medullary blood vessels, and 
reperfusion injury induced by reactive  oxygen species and inflammatory mediators 
released by leukocytes or renal parenchymal cells.  In addition, epithelial injury 
may contribute to persistent intrarenal vasoconstriction through tubuloglomerular 
feedback.  Specialized epithelial cells in the macula densa region of distal tubules 
detect increases in distal salt delivery that occur as a consequence of impaired 
reabsorption by more proximal nephron segments.  Macula densa cells, in turn, 
stimulate constriction of adjacent afferent arterioles by poorly defined mechanism 
and further compromise glomerular perfusion and filtration, thereby contributing to 
vicious circle. 
The recovery phase is characterized by tubular epithelial cell and 
regeneration as well as a gradual return of GFR toward premorbid levels.  The 
recovery phase may be complicated by a marked diuretic phase due to delayed 
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recovery of epithelial cell function (solute water reabsorption) relative to glomerular 
filtration. 
ETIOLOGY  AND PATHOPHYSIOLOGY OF NEPHROTOXIC AKI 
Nephrotoxic ATN may complicate exposure to many structurally diverse 
pharmacologic agents. With most nephrotoxins, the incidence of AKI is in the 
elderly and in patients with preexisting chronic kidney, true or “effective” 
hypovolemia, or concomitant exposure to toxins.  
Radiocontrast agents21, cyclosporine, and tacrolimus cause kidney injury 
through intrarenal vasoconstriction.  Consequently, ATN in asssociation with these 
medications is characterized by an acute fall in renal blood flow and GFR, a 
relatively benign urine sediment, and a low fractional excretion of sodium.  Severe 
cases  may show clinical or pathologic evidence of tubular cell necrosis. Contrast 
nephropathy is also thought to result from the generation of reactive oxygen species 
that are directly toxic to renal tubular cells. Contrast nephropathy classically 
presents as an acute(onset within 24-48 hrs) but reversible (peak 3-5 days, 
resolution with in week) rise in blood urea nitrogen and serum creatinine. Contrast 
nephropathy is most common in individuals with preexisting chronic disease, 
diabetes mellitus, congestive heart failure, hypovolemia or multiple myeloma. The 
type (low vs. isoosmolar contrast) and dose of contrast also influence the likelihood 
of injury associated with administration. 
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Antibiotics and anticancer drugs typically cause ATN through direct toxicity 
to the tubular epithelial cells and/or intratubular obstruction. AKI Complicates      
10-30% of courses of aminoglycoside antibiotics23.  Aminoglycosides accumulate 
in renal tubular epithelial cells, where they cause oxidative stress and cell injury; 
thus, AKI usually occurs after several days of aminoglycoside therapy.  Damage 
may occur in both the proximal and distal tubule; defects in the distal tubule may 
result in decreased concentrating ability.  Amphotericin B causes dose-related AKI 
through intranenal vasoconstriction and direct toxicity to proximal tubule 
epithelium.  Newer (liposomal) formulations of amphotericin B may be associated 
with less nephrotoxicity.  Acyclovir may precipitate in renal tubules and cause 
Acute Kidney Injury.  Foscarnet and pentamidine are less commonly prescribed 
antimicrobials also frequently associated with Acute Kidney Injury.  Cisplatin22 and 
carboplatin, like the aminoglycosides, are accumulated by proximal tubule cells and 
typically provoke AKI after 7-10 days of exposure, typically in association with 
potassium and magnesium wasting.  Ifosphamide administration may lead to 
hemorrhagic cystitis, manifested by hematuria, as well as acute and chronic renal 
failure. Type II renal tubular acidosis (Fanconi syndrome) often accompanies 
ifosphamide-associated AKI. 
Endogenous nephrotoxins include calcium, myoglobin, hemoglobin, urate, 
oxalate, and myeloma light chains24. Hypercalcemia can compromise GFR, 
predominantly by inducing intrarenal vasoconstriction as well as volume depletion 
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from obligate water loss.  Both rhabdomyolysis and hemolysis can induce AKI.  
Common causes of rhabdomyolysis include traumatic crush injury, acute muscle 
ischemia, prolonged seizure activity, excessive exercise, heat stroke or malignant 
hyperthermia, and infectious or metabolic disorders (e.g., hypophosphatemia, 
severe hypothyrodisim).  AKI due to hemolysis is relatively rare and is observed 
following blood transfusion reactions.  It has been postulated that myoglobin and 
hemoglobin promote intrarenal oxidative stress, resulting in injury to tubular 
epithelial cells and inducing intratubular cast formation. In addition, cell-free 
hemoglobin and myoglobin are potent inhibitors of nitric oxide bioactivity and may 
trigger intrarenal vasoconstriction and ischemia. Hypovolemia or acidosis may 
further promote intratubular cast formation.  Intratubular casts containing filtered 
immunoglobulin light chains and other proteins (including Tamm-Horsfall protein 
produced by thick ascending limb cells) cause AKI in patients with multiple 
myeloma (myeloma cast nephropathy)25. Light chains are also directly toxic to 
tubule epitherlial cells.  Intratubular obstruction is an important cause of AKI in 
patients with severe hyperuricosuria or hyperoxaluria.  Acute uric acid nephropathy 
can complicate the treatment of selected lymphoproliferative or myeloproliferative 
disorders (e.g., Burkitt’s lymphoma, acute myelogenous leukemia), especially after 
the administration of chemotherapy, resulting in increased cell lysis (‘tumor lysis 
syndrome’). 
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OTHER CAUSES OF INTRINSIC AKI  
Virtually any pharmacologic agent may trigger allergic interstitial nephritis, 
which is characterized by infiltration of the tubulointerstitum by granulocytes 
(typically but not invariably eosinophils), macrophages, and/or Iymphocytes and by 
interstitial edema.  The most common offenders are antibiotics (e.g., penicillins, 
cephalosporins, quinolones, sulfonamides, rifampin) and NSAIDs. 
Patients with advanced atherosclerosis can develop AKI after manipulation 
of the aorta or renal arteries during surgery or angiography, following trauma, or, 
rarely, spontaneously (atheroembolic AKI). Cholesterol crystals embolize to the 
renal vasculature, lodge in small- and medium-sized arteries, and incite a giant cell 
and fibrotic reaction in the vessel wall with narrowing or obstruction of the vessel 
lumen. Atheroembolic AKI is often associated with hypocomplementemia and 
eosinophiluria, and it is frequently irreversible.  The acute glomerulonephritides and 
immune-mediated diseases characterized by proliferative or crescentic glomerular 
inflammation (glomerulonephritis).  
POSTRENAL AKI 
Urinary tract obstruction accounts for fewer than 5% of cases of hospital-
acquired AKI. Because one kidney has sufficient reserve to handle generated 
nitrogenous waste products, AKI from obstruction requires obstruction to urine 
flow between the external urethral meatus and bladder neck, bilateral ureteric 
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obstruction, or unilateral ureteric obstruction in a patient with one functuioning 
kidney or with significant preexisting chronic kidney disease.  Bladder neck 
obstruction is the most common cause of postrenal AKI and is usually due to 
prostatic disease  (e.g., hypertrophy, neoplasia, or infection), neurogenic bladder, or 
therapy with anticholinergic drugs.  Less common causes of acute lower urinary 
tract obstruction include blood clots, calculi, and urethritis with spasm.  Ureteric 
obstruction may result from intraluminal obstruction (e.g., calculi, blood clots, 
sloughed renal papillae), infiltration of the ureteric wall (e.g., neoplasia), or external 
compression (e.g., retroperitoneal fibrosis, neoplasia or abscess, inadvertent surgical 
ligature). During the early stages of obstruction (hours to days), continued 
glomerular filtration leads to increased intraluminal pressure upstream to the site of 
obstruction. As a result, there is gradual distention of the proximal ureter, renal 
pelvis, and calyces and a fall in GFR.    
AKI IN SPECIAL SETTINGS 
Neonatal AKI is commonly due to immature defence system and 
dehydration. In older children AKI is due to acute diarrhoeal disease, post infective  
glomerulonephritis, hemolytic uremic  syndrome,  and nephritic syndrome.  
In elderly  people incidence of AKI  is high. It may be due to  1) aging 
kidney is less able to cope up with rapid hemodynamic alterations and rapid  
changes in salt and water. 2) High incidence of comorbid illnesses. 3) The elderly 
people consume too many medications in comparing with other age groups. 
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Acute kidney injury in a patient with cancer 
Most AKI in patiens with cancer is due to either prerenal AKI - often 
induced by vomiting and diarrhea in the presence of NSAIDS use -or 
hypercalcemia. Intrinsic  AKI can be triggered by chemotherapeutic agents or by 
the products of tumor lysis51. Renal parenchymal invasion by the solid and 
hematological cancers occurs in 5% to 10% of autopsy studies but it s rarely of 
clinical significance. AKI consequent to leukemia with infiltration of the kidney 
parenchyma typically presents with heamturia, protienuria and enlarged kidneys on 
ultrasound imaging. The diagnosis is a important one because the AKI may respond 
to chemotherapeutic intervention. 
The tumour lysis syndrome is characterized by AKI associated with 
hyperuricemia, hyperphosphatemia and hypocalcemia. It occurs in most often 
following initiation of chemotherapy in patients with poorly differentiated 
lymphoproliferative malignancies, particularly the acute leukemias. It occasionally 
occurs spontaneously or in patients with solid organ tumors. AKI is triggered by 
direct tubular injury/ obstruction by uric acid and calcium phosphate crystals. Less 
common cause of AKI include tumor associated glomerulonephritis or a thrombotic 
microangiopathy(TMA) induced by drugs or irradiation. In regard to the latter, 
chemotherapy-associatd TMA is a well-recognised complications of several 
chemotherapeutic agents of which mitomycin C and gemcytabine are pre- 
eminent51. 
25 
 
AKI in association with multiple myeloma carries a wide differential 
diagnosis with includes in decreasing order of frequency hypovolemia, myloma cast 
nephropathy, sepsis, hypercalcemia,ATN induced by drugs or tumor lysis during 
therapy, light chain deposition disease, cryoglobulinemia, hyperviscosity syndrome, 
plama cell infiltration and vascular amyloidosis25. 
Acute kidney injury in pregnancy 
 In early pregnancy, ATN induced by nephrotoxic abortificients is still a 
relatively common cause of AKI in developing countries but it is rarely seen in 
developed countries. Ischemic ATN, severe toxemia of pregnancy and postpartum 
HUS and TTP are the most common causes later in pregnancy. Ischemic ATN is 
usually provoked by postpartum hemorrhage or abruptio   placentae and less 
commonly by amniotic fluid embolism or sepsis52. Glomerular filtration is usually 
a normal, mild and moderate pre- eclampsia. However AKI may complicate severe  
disease. In this setting, AKI is typically transient and found in association with 
intrarenal vasospasam, marked hypertension and neurologic abnormalities. A 
variant of pre eclampsia, the HELLP syndrome( hemolysis,  Elevated liver 
enzymes, Low platelets), is characterized by an initial benign course that can be 
rapidly deteriorate with the development of a thrombotic microangiopathy 
characterized by hemolysis and derangement of coagulation, and hepatic and renal 
function. Immediate delivery of fetus is indicated in such case .This presentation 
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contrast with that of postpartum thrombotic microangiopathy, which typically 
occurs against a background of normal pregnancy is characterized by postpartum 
thrombocytopenia,microangiopathic anemia, and normal prothromin and partial 
thromboplastin times and frequently causes long term- impairment of renal 
function.  
Acute kidney injury in association with pulmonary diseae53 
The co existence of AKI and pulmonary disease (pulmonary renal syndrome) 
classically suggests a diagnosis of good pasture syndrome, Wegener 
granulomatosis, or other vasculitides. The detection of circulating antineutrophil 
cytoplasmic antibodies, anti glomerular basement membrane antibodies or 
hypocomplementinemia can be useful in differentiation of these diseases. Although 
the urgent need for definitive diagnosis and treatment may mandate a lung or renal 
biopsy. Several toxic ingestions And infections may also cause simultaneous 
pulmonary and renal injury that mimics a vasculitis process. Furthermore intrinsic 
renal and postrenal AKI of any cause may be complicated by secondary 
hypervolemia and pulmonary edema and severe lung disease may compromise 
cardiac output and induce prerenal AKI. 
Acute kidney injury in association with chronic liver disease54 
The differential diagnosis for AKI in association with liver disease is 
similarly large. In chronic liver disease, causes of AKI include volume depletion, 
gastrointestinal  hemorrhage, sepsis, nephrotoxins (antibiotics, radiocontrast )and 
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the HRS. The term HRS is usually reserved for a syndrome of irreversible AKI that 
usually complicates advanced cirrhosis; however this syndrome has been described 
in association with fulminant viral and alcoholic hepatitis54.. The syndrome is 
characterized by renal failure and disturbed regulation of circulatory function. The 
latter is characterized by intense intrarenal vasoconstriction, whereas in the 
extrarenal circulation, arterioral vasodilatation triggers a reduction in total 
peripheral vascular resistance and  a decrease in effective systemic circulatory 
volume despite an expanded total extra cellular fluid. Most patients have clinical 
evidence of  advanced cirrhosis. HRS almost certainly represents the terminal stage 
of a hypoperfusion state that begins early in the course of chronic liver disease. The 
pathogenic mechanisms for the dramatic hemodynamic alternations are 
incompletely understood. In the early stages of HRS. Arterial under filling is 
thought to trigger activation of the rennin angiotensin and sympathetic nervous 
systems. 
Two subtypes of HRS have been described; type1 is characterized by a rapid 
onset of renal failure with a doubling of serum creatinine to greater than 2.5mg/dl or 
a 50% reduction in GFR to less than 20 mL/min over a 2-week period. This subtype 
is characterized by a fulminant course with oliguria, encephalopathy,marked 
hyperbilirubinemia and death usually within 1 month of presentation. Type II HRS 
is typifies in a more indolent course with a stable reduction in GFR accompanying  
diuretic resistant ascites and avid sodium retention. The diagnosis of HRS is one of 
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exclusion. other diagnoses that must be entertained in the patient with AKI and liver 
disease include prerenal AKI due to gastrointestinal losses, drug toxicity, combined 
hepatitis and tubulointerstitial nephritis induced by drugs or infectious agents and 
multiorgan involvement in vasculitides( hepatitis C- induced cryoglobulinemia).  
The BUN and serum creatinine values are characterized deceptively low, despite 
marked impairment of GFR, because of impaired urea generation and co existing 
muscle wasting. The urinary findings include a benign sediment and a low FENa, 
the most common precipitant of the HRS in patients with compensatd cirrhosis is 
spontaneous bacterial peritonitis.  
DIAGNOSTIC EVALUATION OF ACUTELY AZOTEMIA 
PATIENT: 
A detailed and accurate history is crucial to aid in diagnosing the type of 
AKI and determining its subsequent treatment.  A detailed history and a physical 
examination in combination with routine laboratory tests are useful in making a 
correct diagnosis. 
HISTORY 
1. History of acute systemic illness such as gastroenteritis, fever with jaundice, 
(produce AKI by volume depletion, toxic effects). 
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2. History of chronic systemic illness: A previous illness DM, HT, SLE and 
chronic symptoms of fatigue, weightloss, anorexia, nocturia and pruritis all 
suggest chronic kidney disease. 
3.  Other histories useful to find out etiology are 
a. History of trauma especially in unconscious or comatose patient. 
b. History of drug intake like NSAID, ACE inhibitors, antibiotic like 
(pencillin, cephalosporin) may cause interstitial nephritis. 
c. History of intoxication – heavy metal compounds, toluene, cuso4, 
salicylates, ethylene glycol, may explain unexpected episode of AKI. 
d. History of surgery and anaesthesia: 
Both cause vasoconstriction of renal arteries and release of ADH.  As a 
result of reduced volume of urine in early postoperative period,and 
associated  infection with fluid loss leading to prerenal azotemia. 
e. History of unaccustomed exertion – rhabdomyolysis. 
PHYSICAL EXAMINATION 
PRE RENAL AZOTEMIA is the most common cause of acute kidney injury, 
adequacy of ECF volume must be carefully determined. 
Adequacy of effective blood volume 
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 Body weight, postural blood pressure / pulse change, Skin turgor, mucous 
membrane moisture. 
 Recent reduction in body weight, a fall in SBP >10mm Hg or rise in pulse 
>10/min. tenting of upper thorax skin on pinching, dry mucous membrane all are 
suggest reduction in ECF volume. 
Skin 
 Examination of skin for petechiae, purpura and ecchymosis provides clues to 
inflammatory and vascular causes for AKI.  Also help to detect DIC 
hypersensitivity. 
Eyes 
 Evidence of uveitis may indicate interstitial nephritis.  Ocular palsy may 
indicate ethylene glycol poisoning.  Findings suggestive of severe Hypertension, 
endocarditis may be observed after careful examination of eyes. 
 Look for evidence of intoxication (altered mental status, odour on breath or 
clothing, muscle tenderness or edema). 
 Examination of lung, heart, joints, CNS often demonstrate abnormalities. 
 Abdomen – help to detect obstruction at bladder outlet as the cause of renal 
failure, may be due to cancer or enlarged prostate.  Presence of bruit suggests renal 
vascular Hypertension. 
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TESTING PROCEDURES  
URINE ANALYSIS 
 Urine analysis remains the most important test in initial evaluation of AKI. 
Prerenal AKI 
 Urine sediment is characteristically acellular and contains transparent hyaline 
cast (‘band’ “benign” “inactive” urine sediment).  There will be trace or mild 
proteinuria. 
Post renal AKI 
 Trace or no proteinuria, can have hemoglobin, or leukocytes. 
Intrinsic renal AKI 
Intrinsic Renal 
Azotemia 
Proteinuria Sediments 
Ischemic Mild to moderate 
proteinuria 
Pigmented granular cast 
Toxins Mild to moderate 
proteinuria 
Pigmented granular cast 
Acute Interstitial nephritis Mild-Moderate proteinuria 
Haemoglobin , leukocytes 
White cell and white cell 
casts, eosinophils and 
eosinophil casts; redcell. 
 
Occasional uric acid crystals (needle in shape) is common in concentrated 
urine and also suggest urate nephropathy of prerenal AKI. Oxalate (Envelope 
shapped), suggest possibility of ethylene glycol ingestion and toxicity. 
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Muddy brown casts 
  Red blood cell casts 
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URINARY DIAGNO STIC INDICES41 
INDEX PRE RENAL AKI RENAL AKI 
UNa mEq/l <10 >20 
Urinary Osmolality 
(mOsmol/kgH2O) 
>500 <250 
Urine to plasma urea 
nitrogen 
>8 <3 
Ucr to Pcr >40 <20 
Renal failure index UNa 
                                   
   Ucr/Pcr 
<1 >1 
Fractional excretion of Na 
UNa x Pcr x 100 
PNa x Ucr 
<1 >1 
URINE specific gravity >1.020 1.010 
Plasma BUN / creatinine 
ratio 
>20 <10-15 
 
The FENa is the most sensitive index.  However FENa may be >1.0% in 
prerenal AKI if patients are receiving diuretics or have bicarbonaturia (accompanied 
by sodium to maintain electro neutrality), preexisting chronic kidney disease 
complicated by salt wasting or adrenal insufficiency.  In contrast FENa is `<1.0% in 
approximately 15% of patients with nonliguric ischemic or nephrotoxic AKI29, FENa 
is often <1.0 in AKI due to glomerulonephritis, urinary tract obstruction, and 
vascular disease. 
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Blood Urea and Nitrogen 
Although increased levels of BUN and creatinine are the hall marks of renal 
failure, the rates of BUN and creatinine increase are very important.  Creatinine 
rises rapidly within 24-48 hours in patients with AKI following renal ischemia, 
atheroembolization, and radiocontrast exposure.  Peak creatinine levels are 
observed after 3 to 5 days, in contrast nephropathy.  The initial rise in serum 
creatinine is characteristically delayed until the second week of therapy with many 
tubule epithelial cell toxins (eg aminoglycoside, cisplatin), this reflects the need for 
accumulation of these agents within cells before GFR falls. 
RADIOLOGY 
Plain X-ray Abdomen 
 Less expensive, and easily available.  Kidney size, calculi, calcification etc 
can be diagnosed. 
Renal Ultrasound 
 Useful for  1.  Assessing Kidney size. 
   2.  Evaluating obstruction of urinary collecting system 
3.  Useful for detecting intrinsic renal disease which enhances 
renal  echogenicity, however this finding is nonspecific. 
4.  Also aids in performing a renal biopsy 
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Excretory urography 
To make out renal size, hydronephrosis, bladder size, bladder outflow tract 
obstruction. 
Ct scan/MRI  
Alternative imaging modality to USG.  Also useful for evaluation of renal 
mass, retroperitoneal tumor, renal trauma. 
Doppler ultrasound 
For assessment of patency of renal artery and vein in suspected vascular 
obstruction. 
Renal angiography 
Useful in diagnosis of renal vascular disease, including renal artery stenosis, 
renal atherothrombotic disease. 
Nuclear scan    
Radio nucleotide imaging with a Technetium Tc 99m DTPA, 99mTC-DT 
PA and Iodine 13 Hippurate scan can be used to assess renal renal blood flow and 
tubular function. 
RENAL BIOPSY : INDICATIONS41 
1. AKI of unknown cause. 
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2. AKI associated with glomerulonephritis, nephrotic syndrome or 
vasculitis where acute therapy is contemplated. 
3. AKI associated with interstitial disease without a definite cause.  
4.  Prolonged AKI 
NOVEL BIOMARKERS 
New biomarkers hold the promise of allowing clinicians to detect kidney 
injury earlier, to guide future therapy, and to better prognosticate. The currently 
employed, traditional markers of AKI in the blood (creatinine and urea nitrogen) are 
insensitive, lagging indicators that are not specific for any given disease process.  
Novel biomarkers in Acute Renal Failure57-59 
Host Marker  Substrate- test Comments 
Rat SSAT Rat kidney- RT-
PCR and northern 
blot 
SSAT was able to distinguish AKI 
with tubular injury from AKI 
without ATN 
Rat & 
mouse 
CYR61 Kidney and urine- 
western blot 
CYR61 is upregulated in kidneys 
with IRI- able to distinguish prerenal  
from intrarenal AKI 
Human IL-18 Urine- ELISA IL-8 elevated in human kidney ATN 
(native and transplanted kidneys) 
Human NHE3 Urine- 
semiquantitative 
immunoblotting 
NHE3 differentiated prerenal from 
intrarenal causes of AKI 
Human Urine 
proteome 
pattern 
Urine- mass 
spectroscopy 
Humans follwing cardiopulmonary 
bypass surgery-markers at 2 and 6 
hrs postoperatively highly sensitive 
and predictive of AKI 
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Human KIM-1 Urine,kidney- 
multilple methods 
Specific for ischemic AKI/ ATN 
when compared with other forms of 
kidney disease 
Human, 
mouse 
Gro-α, KC Urine, blood- 
ELISA 
Gro-α correlates with renal recovery 
from AKI/DGF in transplant, early 
increase in urine and blood well 
before rise in serum creatinine in 
AKI models 
Human NGAL Blood, urine- 
western blot and 
ELISA 
NGAL sensitive, specific and 
predictive marker of AKI in blood 
and urine of patients after 
cardiopulmonary bypass 
Human Actin,IL-6 
& IL-8 
Urine-dot 
immunoblot and 
ELISA 
All 3 markers predicted prolonged 
AKI following renal transplantation 
in humans  
 
CLINICAL PRESENTATION OF ACUTE KIDNEY INJURY60 
The clinical feature in patients with AKI may vary depending on the 
precipitating cause, the severity of renal injury, and the speed with which it 
develops.  In general AKI can present in one of four ways: 
1. With an unexpected elevation in BUN and serum creatinine 
2. With an alteration in urine flow rate. 
3. With the clinical features of the underlying precipitating cause and 
4. With clinical or biochemical complications of uremia. 
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1.   AN ASYMPTOMATIC ELEVATION  OF BUN OR SERUM CREATININE ON   
ROUTINE BIOCHEMICAL SCREENING 
It is the most common presentation of AKI. Such routine screening has 
increased recognition of milder cases of  AKI which in the absence of oliguria or 
other complications, might otherwise have gone undetected.  However an elevation 
in BUN or serum creatinine concentration does not always signify a reduction in 
GFR and other potential causes should be excluded, such as increased protein 
intake, GI bleed, drug intake (eg. Cephalosporin). 
In most cases of AKI, the rate of increase of BUN and creatinine are 
comparable, ratio of BUN: Creatinine 10 to 20 : 1.  A disproportionate increase in 
BUN may be seen with slow rates of fluid flow along the distal nephron because 
this enhances renal tubular reabsorption of urea nitrogen.  This phenomenon may 
occur in pre renal condition or obstructive uropathy.  In rhabdomyolysis, the serum 
creatinine levels rises more rapidly, by more than 2 mg/dl/day. 
2. ALTERATION IN URINE FLOW RATE 
Oliguria – may be the first clue to presence of kidney injury.  A urine volume 
less than 400ml in 24 hours or <20ml/hour is arbitrarily defined as oliguria because 
this is approximately the minimum volume required to excrete the daily nitrogenous 
waste products when the urine is maximally concentrated. 
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Non oliguric failure (Urine output >500ml/day) :- It is common after 
aminoglycoside nephrotoxicity, burns and administration of radiocontrast dye but it 
may occur with any cause of AKI.  In general non oliguric AKI pretends a better 
prognosis, possibly because it signifies a lesser degree of renal injury. 
Anuria:  passage of less than 50ml of urine per day occurs less commonly 
and indicates a diagnosis of urinary tract obstruction, occasionally seen in RPGN, 
bilateral cortical necrosis and renal infarction.  Alternative Oliguria with Polyuria, 
which is suggestive of incomplete urinary tract obstruction or occasionally with salt 
wasting and polyuria. 
CLINICAL FEATURES OF THE PRECIPITATING CAUSE OF AKI 
AKI has many causes, both extrinsic and intrinsic to kidney.  In each case, 
AKI may present which clinical features related to the underlying cause of renal 
injury.  A thorough history and careful physical examination will be helpful in 
eliciting these features. 
CLINICAL AND BIOCHEMICAL COMPLICATIONS OF AKI 
CLINICAL COMPLICATIONS : 
1. Neurologic complications  
Lethargy and asterixis are neurologic manifestation of uremia that if 
unrecognized and untreated may progress to confusion, stupor, coma, myoclonus 
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and seizures.  Psychiatric manifestations ranging from severe anxiety to psychosis 
can occur.  These complication can be prevented or treated by dialysis34. 
2. Cardiovascular complications  
The most frequent cardiovascular manifestation of AKI is congestive heart 
failure, which is due to fluid overload.  Arrythmias, though common can be due to 
electrolyte abnormalities30.  Hypertension is usually due to volume overload and 
acute glomerulonephritis.  Pericarditis occurs with advanced uremia. 
3. Hematologic complications  
Hematologic complications include anemia, (due to inhibition of 
erythropoiesis, bleeding, hemodilution, shortened red cell life span)31 leukocytosis, 
defective platelet function (due to presence of uremic toxins in plasma), usually 
improves with dialysis.  However, the response to dialysis is often incomplete.  
Administration of cryoprecipitate or the vasopressin analogue deamino – 8 – d – 
arginine vasopressin (DDAVP) both improve platelet function in uremia and 
prolonged bleeding time32. 
4. Gastro intestinal complications  
Anorexia, nausea and vomiting are frequent early symptoms. Erosive 
gastrointestinal ulcers may develop in any part of GI tract, bleeding from these 
ulcers may be severe and is important cause of death in AKI33.  Hiccups are a late 
sign occurring in patients with advanced uremia. Presence of Jaundice is 
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suggestive of hepatic injury secondary to passive congestion, ischemia or 
intraabdominal sepsis and is a poor prognostic sign.  Mild hyperamylesemia due to 
reduced renal excretion of amylase. 
5. Nutritional and metabolic complications  
Hypercatabolism may be releated to uremia per se or is attributable to 
infection or other acute stress.  It has been suggested that elevated parathyroid 
hormone and metabolic acidosis in AKI may accelerate protein catabolism35.  
Elevated levels of cytokines such as interleukins – 1 and TNF α particularly 
present in septic patients also contribute to catabolic state.  In many patients with 
AKI, combination of catabolic factors, hormonal imbalance and reduced dietary 
intake results in negative nitrogen balance.  Mild hyperuricemia occurs in AKI, 
rarely the level exceeds 15 mg/dl. 
6. Infectious complications  
Between 50 – 90% of patients with AKI develop infections and this high 
incidence does not appear to be reduced by use of prophylactic antibiotics.  The 
major predisposing factors are: Frequent use of indwelling catheters, and use of 
peripheral and central intravenous lines for invasive monitoring and as access for 
hemodialysis.  The most frequent sites involved are chest, urinary tract and wounds.  
The predisposition to serious infection due to defective chemotaxis, absolute or 
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relative agranulocytosis, relative lymphopenia and impaired cell mediated 
immunity. 
7. Respiratory complications 
Pulmonary edema and pneumonia are the common complications.  ARDS, 
seen in critically ill patients with multiorgan failure. 
BIOCHEMICAL COMPLICATIONS OF AKI 
Abnormalities of fluid and electrolyte metabolism 
Fluid retention as a result of decreased salt and water excretion leads to 
pulmonary edema, cerebral edema, hyponatremia.  Fluid overload is common in 
oliguric patients, surgical patients who receive large quantities of IV fluids 
perioperatively and in patients requiring fluids for resuscitation.  The administration 
of sodium bicarbonate may be a contributory factor. 
Hyponatremia due to excessive administration of hypotonic fluids may be 
accompanied by lethargy, progressive obtundation and seizures. 
Hyperkalemia is one of the serious complications of AKI.  In patients with 
mild AKI, the serum potassium increases by 0.5 to 1.0 meq/l/day, but in patients 
who are hypercatabolic with extensive tissue injury or hemolysis, the rate of 
increase is rapid, by 1 to 2 meq/l in only a few hours. 
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K+ level 5.5 to 6.5 mEq/L produces tall peaked T waves and shortening of 
QT interval.  With level of 6.5 to 7.5 meq/L QRS complex widend, P wave 
decreases in amplitude, PR interval is prolonged, ventricular tachycardia is 
common, and ventricular fibrillations or asystole may be a terminal event37. 
Hypokalemia may be seen rarely in AKI caused by Cisplatin or 
Amphotericin B induced nephrotoxic non oliguric renal failure. 
Metabolic acidosis 
In normal person, the metabolism of dietary protein results in daily 
generation of about 1mEq of fixed, non volatile acids per kg of bodyweight.  In 
AKI, the failure to excrete these acids results in development of metabolic acidosis.  
In patients with uncomplicated AKI, the serum bicarbonate falls by about 1 to 2 
mEq/l/day38.  In hypercatabolic state, the fall of plasma biocarbonate level is faster. 
Abnormalities of divalent cation metabolism39 
 Hypocalcemia is due to retention of phosphate secondary to reduction in 
GFR, skeletal resistance to calcemic action of parathyroid hormone, and decreased 
blood level of 1,25 – dihydroxy Vitamin D40.  Hypocalcemia causes a fall in resting 
membrane potential with an increase in muscle irritability.  It is usually 
asymptomatic in AKI, possibly because co-existing metabolic acidosis increases the 
level of serum ionized calcium counter balancing its effect on neuromuscular 
excitability.  Clinically, the symptoms include perioral paresthesias, muscle 
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twitching, hallucinations, and seizures.  Latent tetany may be evident on physical 
examination.  ECG changes include prolonged QT interval. 
Hypercalcemia : is due to reduced renal excretion and in some patients by 
the release of intracellular phosphate.  It is seen with severe tissue break down as in 
rhabdomyolysis and tumour lysis syndrome.  Mild degree of asymptomatic 
hypomagnesemia due to nephrotoxic drugs such as amphotericin B.  
Hypermagenesemia (due to injudicious use of magnesium containing antacids or 
laxatives) also seen in AKI. 
MANAGEMENT OF ACUTE KIDNEY INJURY 
PREVENTION 
The initial approach to patients with AKI must be focussed on preventing 
further injury to the kidney.  In many cases this can be achieved by removing the 
underlying cause and correcting fluid and electrolyte imbalance.  There is no 
specific therapy for ischemic or nephrotoxic AKI.  Prevention is important. 
1. Careful monitoring of systemic hemodynamics and volume states, 
especially in elderly and those with preexisting renal insufficiency. 
2. Aggressive restoration of intravascular volume reduces the incidence of 
ischemic AKI after major surgery, burns, trauma or cholera. 
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3. The incidence of nephrotoxic AKI can be reduced by tailoring the dosage 
of potential nephrotoxins to body size and GFR. 
4. Hypovolemia should be avoided in patients receiving nephrotoxic 
medications as renal hypoperfusion potentiates the toxicity of most. 
Prophylactic use of several regimens to increase renal perfusion (eg. 
Vasodilators, dopamine, atrial natriuretic peptide) or to maintain high urinary flow 
(mannitol, loop diuretics) appears to be a logical approach. 
SPECIFIC THERAPIES64 
Prerenal azotemia is rapidly reversible on restoration of renal perfusion.  The 
composition of replacement fluids for treatment of hypovolemia varies depending 
on the source of fluid loss. Hypovolemia caused by hemorrhage is ideally corrected 
with packed red cells if the patient is hemodynamically unstable or if the hematocrit 
is low. Isotonic saline is usually appropriate replacement for mild to moderate 
hemorrhage or plasma loss (e.g burns, pancreatitis). Urinary and gastrointestinal 
fluids are hypotonic.  Initial replacement is by hypotonic solutions (eg. 0.45% 
saline), and subsequent therapy should be on measurements of volume and ionic 
content of excreted or drained fluids.  Cardiac failure may require aggressive 
management with positive inotropes, preload and after load reducing agents, 
antiarrhythmic drugs, and mechanical aids such as intra aortic balloon pumps. 
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Fluid management is challenging in patients with AKI and cirrhosis.  The 
relative contribution of hypovolemia to AKI is determined only by administration 
of fluid challenge, often with invasive monitoring of systemic hemodynamics.  
Fluids should be administered slowly, as non responders may suffer an increase in 
ascites formation and/or pulmonary edema.  Large volume paracentesis will 
improve GFR, possibly by lowering intra abdominal pressure and promoting blood 
flow in renal veins. 
INTRINSIC AKI 
A variety of agents have been tested for their ability to attenuate injury or 
hasten recovery in ischemic and nephrotoxic ATN. However, none was consistently 
been shown to benefit.  These include strategies to increase renal blood flow and 
urine flow (e.g. lowdose dopamine, atrial natriuretic peptide, mannitol, loop 
diuretics), relieve tubular obstruction (e.g RGD peptide), reduce epithelial cell 
swelling (eg mannitol), replenish cell ATP level (Mg ATP), scavenge oxygen free 
radical, (e.g superoxide dismutase, catalase, mannitol), inhibit leukocyte endothelial 
cell adhesion during reperfusion (e.g anti-CD18, anti ICAM-1 or anti-p-selectin 
monoclonal antibodies) stimulate cellular regeneration (e.g. epidermal growth 
factor, aminoacid infusion) and prevent accumulation of intracellular calcium (e.g. 
calcium channel blocker). 
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AKI caused by other intrinsic renal disease such as acute glomerulonephritis 
or vasculitis may respond to corticosteroids, alkaylating agents and/or 
plasmapheresis, depending on primary disease.  Aggressive control of systemic 
arterial pressure is of paramount importance in limiting renal injury in malignant 
hypertensive nephrosclerosis, toxemia of pregnancy and other vascular diseases.  
Hypertension and AKI associated with scleroderma may be exquisitely sensitive to 
treatment with ACE inhibitors.  Antiplatelet agents, plasma exchange, and plasma 
infusion are useful in treatment of HUS and TTP. 
POST RENAL AKI 
Obstruction of urinary tract should be treated by appropriate surgical 
procedure.  Eg. Removal of calculus. 
SUPPORTIVE MEASURES 
DIET AND FLUIDS 
1. Fluid intake should be restricted to 500 ml plus measured losses. 
2. Salt (1-2g/d), potassium intake (<40mmol/d), and phosphate intake 
(<800mg/d) is essential. 
3. Calorie intake of at least 2000 kcl/day restricts the catabolism of protein 
for energy and slows the formation of nitrogenous metabolites. 
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HYPERKALEMIA 
If untreated may lead to ventricular tachycardia and death.  Restrict dietary 
K+ intake, eliminate K+ supplements, K+ sparing diuretics Potassium binding ion 
exchange resins, (eg, sodium polystyrene sulphonate) administrated orally or 
rectally, can bind potassium in the gut.  Extracellular potassium concentrations can 
be temporarily lowered by administering glucose and insulin.  Calcium gluconate 
(10ml of 10% solution over 5 min intravenous) will buffer the effects of potassium 
on myocardium.  Dialysis is indicated if hyperkalemia is resistant to these measures. 
MANAGENT OF ISCHEMIC AND NEPHROTOXIC ACUTE KIDNEY 
INJURY64 
Management Issue     Therapy 
Reversal of Renal Insult 
 
Ischemic ATN Restore systemic hemodynamics and renal perfusion 
through volume resuscitation and use vasopressors. 
Nephrotoxic ATN Eliminate nephrotoxic agents Consider toxin-specific 
measures: e.g., forced alkaline dieresis for 
rhabdomyolysis, allopurinol/ rasburicase for tumor lysis 
syndrome. 
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Prevention and Treatment of Complications 
------------------------------------------------------------------------------------------------------------- 
Intravascular volume overload Salt and water restriction, Diuretics, 
Ultrafiltration 
 
Hyponatremia Restriction of enteral free water intake, 
Avoidance of hypotonic intravenous 
solutions, including dextrose-containing 
solutions. 
 
Hyperkalemia Restriction of dietary K+ intake, Eliminate 
K+ supplements and K+ sparing diuretics, 
Loop diuretics to promote K+excretion, 
Pottassium binding ion-exchange resins 
(e.g., sodium polystyrene sulfonate or 
Kayexelate), Insulin (10 units regular) and 
glucose (50 mL of 50% dextrose) to 
promote intracellular mobilization, inhaled 
β-agonist therapy to promote intracellular 
mobilization. Calcium gluconate or 
calcium chloride (1g) to stabilize the 
myocardium, Dialysis. 
Metabolic acidosis Sodium bicarbonate (maintain serum 
bicarbonate >15 mmol/L or arterial pH     
> 7.2) 
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Administration of other bases, e.g., 
THAM ,Dialysis. 
Hyperphosphatemia Restriction  of dietary phosphate intake, 
Phosphate binding agents (calcium 
carbonate, calcium acetate, sevelamer 
hydrochloride, aluminum hydroxide). 
Hypocalcemia Calcium carbonate or gluconate (if 
symptomatic) 
Hypermagnesemia   Discontinue Mg++ containing antacids. 
Hyperuricemia Treatment usually not necessary if <890 
µmol/L or <15mg/dL. 
Allopurinol, forced alkaline dieresis, 
rasburicase. 
Nutrition Protein and calorie intake to avoid net 
negative nitrogen balance. 
Dialysis To prevent complications of acute kidney 
injury. 
Choice of agents Avoid other nephrotoxins: ACE 
inhibitos/ARBs, aminoglycosides, 
NSAIDs, radiocontrast unless absolutely 
necessary and no alternative. 
Drug dosing Adjust doses and frequency of 
administration for degree of renal 
impairment. 
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RENAL REPLACEMENT THERAPY : DIALYSIS 
Dialysis replaces renal function until regeneration and repair, restore renal 
function Indications41  are 
1. Symptomatic uremia 
(asterixis, encephalopathy etc),   
2. Acidosis-  refractory to medical treatment     
3. Hyperkalemia- refractory to medical treatment     
4. Volume overload- refractory to medical treatment     
Types of dialysis available are peritoneal, hemodialysis or hemofiltration.  
Dialysis modality is choosen according to the needs of individual patients (e.g., 
peritoneal dialysis may be preferable if the patient is hemodynamically unstable, 
haemodialysis after abdominal surgery involving peritoneum), the expertise of the 
nephrologist and the facilities of institution. 
PERIOTONEAL DIALYSIS 
Is simple, safe, relatively “Low tech” and portable42.  An intact abdomen is 
essential for efficient function.  It is achieved by insertion of a single lumen cuffed 
catheter into peritoneal cavity.  Sterile electrolyte (dialysate) solution is infused into 
the abdomen and allowed to dwell for a short period.  Metabolites diffuse from the 
capillaries through the peritoneal membrane while the fluid is in peritoneal cavity.  
Repeated exchanges will slowly remove urea, creatinine, Potassium etc.  A high 
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concentration of glucose in the dialysate acts as an osmotic agent.  It is less efficient 
than hemodialysis.  
Benefits of peritoneal dialysis include avoidance of systemic anticoagulation 
and need for angioaccess.  Systemic hypotension is typically avoided.  Drawbacks 
include the risk of visceral injury during catheter placement and peritonitis 
subsequently. With the development of Intermittent hemodialysis and more recently 
the slow continuous blood purification therapies there has been decline in the use of 
peritoneal dialysis in acute setting43. 
HEMODIALYSIS 
Is more efficient than peritoneal dialysis.  Vascular access for intermittent 
hemodialysis is best achieved by insertion of a temporary double-lumen 
hemodialysis catheter into the internal jugular vein.  The subclavian and femoral 
veins are alternative access sites.  Anticoagulation with heparin is standard method 
of preventing thrombosis of the extra corporeal circuit during acute intermittent 
dialysis45.  Hemodialysis uses a synthetic membrane in the artificial kidney or 
dialyser.  The choice of membrane used during dialysis may have an effect on 
outcome.  Several randomized controlled trials indicate maintenance phase of ATN 
is significantly shorter with use of more biocompatible synthetic dialysis membrane 
than with conventional cuprophane or cellulose acetate membranes probably 
because of less activation of blood complement, leukocytes and other mediator 
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system44.  By ultrafiltration excess body fluid can be removed by placing a pressure 
difference across membrane.  The machine manufactures dialysate from purified 
water and a concentrated electrolyte solution, checks its composition and 
temperature and passes it on to the dialyses. 
Complication of acute intermittent hemo dialysis 
1. Hypotension 
2. Muscle cramps 
3. Dialysis disequilibrium syndrome : Typically occurs after a first dialysis 
in very uremic patients.  It is self limited, characterized by nausea, 
vomiting, headache, altered consciousness and rarely seizures or coma.  It 
is due to rapid movement of water into brain cells following development 
of transient plasma hypo-osmolality as solutes are rapidly cleared from 
bloodstream during dialysis. 
4. Anaphylactoid reactions to dialyzer on its first use, rarely seen46 
For those who do not tolerate intermittent hemodialysis, and peritoneal 
dialysis, continuous arteriovenous hemodiafiltration (CAVH) and continuous 
venoveous hemodiafiltration (CVVH) are alternative techniques for treatment of 
AKI. 
 
 
54 
 
PROGNOSIS OF AKI 
The mortality rate among patients with AKI approximates 50% and has 
changed little over the past 30 years despite of advent of improved nutritional 
therapy, refined dialysis technique, advances in antibiotic therapy.  This may be 
explained by the two demographic changes: the age of the patients continues to rise, 
and co-existing serious illnesses are increasing among patients47.  It should be 
stressed, however that patients usually die from sequalae of the primary illness that 
induced AKI and not from AKI. 
The mortality rates vary greatly depending on the cause of AKI: 15% in 
obstetric patient, 30% in toxin related AKI and 60% following trauma or major 
surgery.  If the renal failure is mild, the mortality rate is 30-60% and if the patient 
need dialytic therapy, the mortality rate is 50-90%.  Mathematical models for 
outcome of AKI in critically ill patients ( Apache II, Billock, cioffi) are not reliably 
predictive.  However death is almost universal if AKI is associated with failure of 
more than three other organ systems48. 
Non oliguric AKI carries better prognosis than oliguric AKI, partly because 
management of fluid and electrolyte abnormalities is easier and these patients have 
a less severe renal insult.  The influence of age as independent risk factor for 
mortality is not fully defined.  Most patients who survive an episode of AKI recover 
sufficient renal function to live normal lives. 
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PROGNOSTIC FACTORS IN AKI 
General Controversial 
Hypotension 
Sepsis 
Oliguria 
Need for assisted ventilation 
Severity of renal failure 
Failure of other organs 
Nature of underlying illness 
Age over 65 years  
Magnitude of rise in serum 
creatinine 
 
Early diagnosis, prevention, and treatment of sepsis, prevention of 
complications of uremia are the major goals of management in AKI patients49. 
OUTCOMES 
                       The crude mortality rate among patients with intrinsic AKI 
approximates 50% and has changed little over the past 3 decades. The lack of 
improvement in outcome, despite significant advances in supportive care may be 
more apparent than real and reflect a reduction in the percentage of isolated AKI 
combined with an increase in AKI complicating the multi organ dysfunction 
syndrome. When allied with the current trend for more aggressive surgical and 
medical intervention in ageing population. These factors probably mask an 
improvement in outcome. Mortality rates differ markedly depending on the cause of 
AKI: being approximately 15% in obstetric patients, 30% in toxin related AKI, and 
60% to 90% in patients with sepsis60.  
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MATERIALS AND METHODS 
 
Place                : Department of Medicine 
Design              :    Observational Study 
Period               : September 2007  to September 2008 
Sample Size      :    100 Patients 
Collaborating Departments :     Nephrology 
Inclusion Criteria 
An absolute increase in serum creatinine of more than or equal to 0.3 mg/dl 
(≥ 26.4 µmol/l), a percentage increase in serum creatinine of more than or equal to 
50% (1.5-fold from baseline) 
Exclusion Criteria 
1.  Patients with chronic kidney disease 
2.  Patients with abnormal kidney size and abnormal  corticomedullry      
Differentiation 
A thorough diagnostic evaluation was made by a detailed history,  physical 
examination, urine analysis, complete hemogram, renal function tests, renal 
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ultrasound in appropriate places, serology for leptospirosis, enteric fever, and smear 
for malaria and other relevant investigations to find out  the etiological diagnosis.  
The proforma used for the same is attached. 
Once the diagnosis was made, the patients were started on appropriate 
therapy. Wherever possible the etiological factors were treated or the offending 
agents withdrawn. Renal replacement therapy was given according to the standard 
clinical and biochemical indications. 
Ethical Committee approval was obtained. 
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OBSERVATIONS & DATA ANALYSIS 
Total Number of Patients –100  
                             Male   57 
                             Female               43 
                             Age group range  13-85 yrs  
                             Mean age    41.4 
The most common clinical features observed in our study were oliguria 
(88%), vomiting (64%), facial puffiness (53), loose stools (51%), pedal oedema 
(47%), altered sensorium (13%), jaundice (11%).                              
                                                        TABLE – 1 
AGE DISTRIBUTION ACUTE KIDNEY INJURY IN OUR STUDY 
 
AGE(Years) 
 
MALE 
 
FEMALE 
 
TOTAL (n=100) 
 
13 – 20 
 
8 
 
9 
 
17 
 
21 – 30 
 
12 
 
8 
 
20 
 
31 – 40 
 
4 
 
8 
 
12 
 
41 – 50 
 
13 
 
7 
 
20 
 
51 – 60 
 
10 
 
7 
 
17 
 
> 60 
 
10 
 
4 
 
14 
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In our study more cases occurred in second & fourth decades. In our study we 
got about 14 cases in >60 yrs. In that about 10 patients were included in risk, 1 
patient in injury & 3 patients in failure based on RIFLE criteria. Two patients were 
treated with hemodialysis & remaining cases treated conservatively. Two cases 
were died of complications during the management mainly due to cardiovascular  
complications. 
                                                  TABLE - 2 
PRESENTING FEATURES OF AKI IN OUR STUDY 
 
URINE 
OUTPUT 
Male Female Total (n – 100) 
 
OLIGURIC 
 
50 
 
38 
 
88 
 
NONOILGURIC 
 
 
7 
 
 
5 
 
12 
 
60 
 
TABLE – 3 
ETIOLOGICAL PROFILE AKI IN OUR STUDY 
ETIOLOGY Males Females Total(n=100) 
ADD 23 21 44 
SEPSIS 6 4 10 
MALARIA 5 3 8 
LEPTOSPIROSIS 2 2              4 
LEPTO+ 
MALARIA+ 
ENTERICFEVER 
 
8 
 
4 
 
12 
POISONING 6 2 8 
GLOMERULO 
NEPHRITIS 
0 5 5 
SNAKE BITE 2 3 5 
DRUG INDUCED 1 1 2 
POST RENAL (BPH, 
CALCULUS) 
2 0 2 
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 In our study, maximum cases of AKI were due to acute diarrheal 
diseases (44%). The next one was infections (34%) like malaria (including 
complicated), leptospirosis, enteric fever and combination of above infections.  
Poisoning(8%) occupies the next position(includes cuso4 poison, dichromate 
poison, paracetamol poison, & unknown poison). My study also contain 
glemerulonephritis (5%), snake bite (5%), drugs (2%-ACEI, NSAIDS), 
postrenal(2%) as  causes of remaining AKI. 
 TABLE – 4 
CAUSES OF NONOLIGURIC AKI  IN OUR STUDY 
CAUSES CASES 
ADD 3 
POISONING 3 
DRUG INDUCED 2 
SNAKE BITE 2 
SEPSIS 1 
MALARIA 1 
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TABLE – 5 
ETIOLOGY OF ACUTE KIDNEY INJURY IN OUR STUDY 
ETIOLOGY NO OF 
CASES 
PRERENAL RENAL POSTRENAL 
ADD 44 40 4 0 
SEPSIS 10 1 9 0 
MALARIA 8 5 3 0 
LEPTOSPIROSIS          4 4 0 0 
LEPTO+ 
MALARIA+ 
ENTERICFEVER 
12 10 2 0 
POISONING 8 3 5 0 
GLOMERULO 
NEPHRITIS 
5 0 5 0 
SNAKE BITE 5 0 
 
5 0 
DRUG INDUCED 2 1 1 0 
POST RENAL 
(BPH, 
CALCULUS) 
2 0 0 2 
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TABLE – 6 
AKI- RIFLE DITRIBUTION IN OUR STUDY  
ETIOLOGY NO OF 
CASES 
RISK INJURY FAILURE 
ADD 44 28 10 6 
SEPSIS 10 0 0 10 
MALARIA 8 2 2 4 
LEPTOSPIROSIS          4 3 1 0 
LEPTO+ 
MALARIA+ 
ENTERICFEVER 
12 10 1 1 
POISONING 8 1 4 3 
GLOMERULO 
NEPHRITIS 
5 0 5 0 
SNAKE BITE 5 1 
 
1 3 
DRUG INDUCED 2 1 1 0 
POST RENAL 
(BPH, 
CALCULUS) 
2 0 1 1 
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RIFLE DISTRIBUTION OF AKI 
46
26
28
RISK 
INJURY
FAILURE
 
TABLE – 7 
 ACUTE KIDNEY INJURY-TREATMENT 
 NO OF 
CASES 
CONSERVATIVE HD PD 
RISK 46 46 0          0 
INJURY 26 15 10 1 
FAILURE 28 10 17 1 
 
AKI -TREATMENT
46
15
10
0
10 17
1 1
0
5
10
15
20
25
30
35
40
45
50
RISK(46) INJURY(26) FAILURE(28)
PD
HD
CONSERVATIVE
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 In our study based on RIFLE criteria 46 patients were included in risk, 
26 in injury, 28 in failure. In risk all patients were treated conservatively & all 
patients survived. In injury 57.6% of patients were treated conservatively, 42.3% of 
patients were dialysed & one patient died. In failure 35.7% of patients were treated 
conservatively, 64.2% of patients were treated with dialysis and 12 patients died. 
 The frequency of peritoneal dialysis is decreased so drastically because 
of availability of Hemodialysis and higher efficiency of hemodialysis. In our study 
about 26% of patients had complications and 13 patients (50%) were treated 
successfully. 
TABLE – 8 
ACUTE KIDNEY INJURY-OUTCOME 
 
 
NO OF 
CASES 
SURVIVED EXPIRED 
RISK 46 46 0 
INJURY 26 25 1 
FAILURE 28 16 12 
 
66 
 
TABLE – 10 
HOSPITAL ACQUIRED  AKI 
ETIOLOGY CASES 
SEPSIS 8 
DRUGS 2 
 
COMMUNITY vs  HOSPITAL ACQUIRED AKI
90
10
COMMUNITY
HOSPITAL
 
 In our study about 10 patients  were hospital  acquired  AKI. In that 
4(40%)  patients  were treated with  hemodialysis, 6(60%)   patients  were   treated 
conservatively, In that  5 (50%) of patients  were treated successfully.  
TABLE – 9 
ACUTE KIDNEY INJURY-COMPLICATIONS 
COMPLICATIONS CASES 
METABOLIC 10 
CARDIOPULMONARY 12 
GIT 2 
CNS 2 
TOTAL 26 
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DISCUSSION 
Acute kidney injury is a potentially fatal, but reversible renal disease. The 
etiology, course , outcome, differ in various parts of india due to its climatic & 
geographic diversity & the varying standards of medical care. 
In our study 100 patients were  analysed , there were 57 males & 43 females. 
The median age was  41.4.  . Maximum number  of cases occurred in the second & 
fourth  decade   . 
In our study  oliguric  AKI  predominate (88%). This is in concordance  with 
a previous study by Dr.M.A.Muthusethupathi et al 67  in 1991. 
Acute diarrhoeal disease was the leading cause of AKI in our study. Cengiz 
utas et al66  from turkey reported diarrhoeal   disease  was the commonest cause  of 
AKI. Dr.M.A.Muthusethupathi et al67   reported that leptospirosis was the leading 
cause of AKI in chennai. 
Acute diarrhoeal disease was the leading cause of AKI in our study. Of 
44(44%) patients 5 (11.3%) patients were treated with dialysis  (Peritoneal 
Dialysis=2, Hemodialysis =3), 39(88.6%) cases  treated conservatively. One patient 
died due to arrythmia . The mortality observed  during the study was 2.2%, which is  
less when compared with the reports of a study by   Dr.M.A.Muthusethupathi et 
al 67 (34.7%) . SK Agarwal et al65 in their study reported  11% cases of AKI was  
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due to diarrhoeal dieases in north India . Awareness of early rehydration therapy 
and early referral to higher centers contribute to decline in mortality. 
Malarial AKI was observed in 8(8%) cases.  In Dr.M.A.Muthusethupathi 
et al 67 study no cases were reported. A study by  Prakash J et al68   from eastern 
india reported  4.2 % cases were reported. Out of 8 cases 4  cases were  treated with 
hemodialysis  and 4 cases were  treated  conservatively. The mortality observed in 
our study  was  25%  in contrast with 42.5% in Zinna S et al36. Two patients 
presented with cerebral malaria with renal failure. One patient had metabolic 
acidosis, One patient had arrhythmias, One patient had hypotension. Mortality 
decreased  mainly due to earlier diagnosis and earlier use of  hemodialysis. 
We have 4 (4%)  patients 0f leptospirosis with AKI as compared  to 
Dr.M.A.Muthusethupathi et al67 study in which the incidence of leptospirosis  
was  41% . we confirmed the cases based on modified faine’s criteria. Of 4 patients 
3 patients were treated conservatively,  one patient was treated with hemodialysis. 
There was no mortality in our study . In the study by Dr.M.A.Muthusethupathi   
et al67 the mortality was 20.8%. The low mortality is mainly due to awareness of 
leptospirosis, its standard diagnostic criteria(modified faine’s criteria), therapy and 
early referral to higher center . 
In contrast with other studies our study had significant number of patients 
with the combination of leptospirosis, malaria, enteric fever. In other studies, no 
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such combinations were reported. Of 12(12%) patients, 10 (80%) were treated 
conservatively, two patients were treated with hemodialysis. We also had 
significant number of  sepsis (10%) as a cause of AKI. Of 10 patients 4(40%)  
patients were  treated conservatively, 6(60%)  patients were treated with 
hemodialysis. The mortality was  higher (70%). It may be  due to association  with  
comorbid illnesses (eg. Diabetes), and higher incidence of multi organ dysfunction 
syndrome in these patients. 
AKI due to cupper sulphate poisoning contributes about  3(3%) . All 3  
patients were treated with Hemodialysis and recovered. In 
Dr.M.A.Muthusethupathi et al67 study the incidence was 3.4% and the mortality 
was 37.5%.  In   Prakash J et al68 study no cases were reported. All 3 patients in 
our study came under the ‘Injury ‘criteria. One patient developed metabolic acidosis 
and was, treated with dialysis successfully. Another 2 patients developed AKI after 
dichromate poisoning, Both patients were treated with hemodialysis . Both patients 
developed metabolic acidosis and one patient died.  Another 2 patients developed 
AKI after unknown poisoning, one patient was treated with hemodialysis. Both 
patients developed metabolic acidosis and  one patient died.  One patient developed 
AKI after paracetamol poisoning and was treated with hemodialysis. There was not 
many studies on dichromate and  paracetamol poisoning with  acute kidney injury. 
The 5 patients had snake bite as a cause of  AKI. 4(80%) patients were 
treated with hemodialysis. The mortality Was 20%. In  Dr.M.A.Muthusethupathi 
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et al67 study the incidence was 4.7% and the mortality was 34.7%.  In  Prakash J  
et al 68 study no case of snake bite  was  reported. In our series mortality is mainly 
due to delay in seeking  early  treatment as most of the patients were from rural 
areas. 
In our study, 5(5%) patients had glomerulonephritis. All patients were 
treated   conservatively and recovered. AKI due to glomerulonephritis was  8.5%  
in  Dr.M.A.Muthusethupathi et al  study . 
 
AKI due to drugs contribute 2(2%) of patients. One patient was hypertensive 
and developed acute kidney injury, when he was started on ACEI, however his 
renal Doppler was normal, and he recoverd. One patient was diagnosed to have 
rheumatoid arthritis, and developed acute kidney injury with NSAIDS and 
recovered with conservative management.  In Prakash J et al68 study the incidence 
was 2% which was similar to our study.  
AKI due to Postrenal (surgical) causes contribute 2(2%) of patients. One 
patient had bilateral l staghorn calculi treated surgically, and he recovered. One 
patient had BPH of grade 3 and was treated surgically. He recovered. This is similar 
to a previous study by Dr.M.A.Muthusethupathi et al 67 in 1991(2.5% incidence). 
Of  total 100 cases 46  patients came under RISK  based on “RIFLE” criteria. 
In that 100% patients were treated successfully with conservative management. The 
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mortality of RISK in our study was  nil.  About 26 patients came under INJUR.  In 
that 15 (57.6%) patients treated conservatively, 11(42.3%) patients were treated 
with dialysis. The mortality in INJURY was 3.8%. About 28 patients came under 
FAILURE.  In that 10 (35.7%) patients were treated conservatively, 18 (64.2%)   
patients were treated with dialysis. The mortality in FAILURE was 46.1%. 
Ostermann M, Chang RW: CCM 200763  detected the following  RIFLE class F 
have a mortality of  57%, RIFLE class I  45%   RIFLE class R 21%. There was an 
association between acute kidney injury and hospital outcome, but associated organ 
failure, had a greater impact on prognosis than severity of   acute kidney injury.    
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CONCLUSION 
The presentation   of AKI  is predominatly  oliguric . But nonoliguric AKI 
should be  born in mind. 
Acute diarrhoeal disease still remains the most common cause of acute 
kidney injury. Mortality observed during the study is very low when compared the 
previous studies.Awareness of early rehydration therapy and early referral to higher 
centers contribute to decline in mortality.  
 
Infections occupies  significant place in the etiology of AKI, which includes  
malaria (including complicated), leptospirosis, enteric fever, and combination of 
above infections.  Regarding sepsis we have  to prevent the multi organ failure or 
we have to treat  the multi organ failure very aggressively to reduce the higher 
mortality associated with  sepsis. 
Majority of our patients were managed conservatively 
When dialysis is indicated for clinical or biochemical reasons, 
HD is the preferred mode of dialytic support. PD is begun only when HD is 
Not available or is contraindicated 
Main issues obtained were, 
                                      
             1.     About two-third of patients with AKI can be managed by conservative  
  measures alone.  
             2.     About  one-third of patients needed dialysis, 
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Delayed diagnosis and treatment, pulmonary and other infections, the 
frequent presence of complicating features and the multi organ dysfunction 
syndrome  are the chief reasons for the mortality rate in our study. 
The frequency of peritoneal dialysis is decreased so drasticaly                                           
because of  availability of hemidialysis and higher efficiency of hemodialysis.   
 
The RIFLE classification was suitable for the definition of acute kidney 
injury in all type of medical settings. There was an association between acute 
kidney injury and hospital outcome, but associated organ failure, had a greater 
impact on prognosis than severity of   acute kidney injury.       
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CLINICAL  PROFILE OF  ACUTE  KIDNEY INJURY DUE TO MEDICAL 
DISORDERS IN CHENNAI 
NAME:                                            AGE: 
SEX :                                  OCCUPATION : 
IP NO  : 
PRESENT ILLNESS      
    OLIGURIA                                                           Y/ N 
    PEDAL OEDEMA                                                     Y/N 
    FACIAL PUFFINESS                                                 Y/N 
    HAEMATURIA                                                          Y/N 
    THIRST                                                                     Y/N 
    ORTHOSTATIC  DIZZINESS                                   Y/N 
    LOOSE STOOLS                                                       Y/N 
    VOMITING                                                              Y/N 
    GI HEMORRHAGE                                                  Y/N 
    BURNS                                                                     Y/N 
    TRAUMA                                                                 Y/N 
    BREATHLESSNESS                                                  Y/N 
                  NYHA CLASS 
                  1. PND/ORTHOPNOEA 
     ASCITIS                                                                    Y/N 
   DRUG INTAKE                                                    Y/N 
                     DRUG NAME: 
                     DURATION  : 
   ABDOMINAL PAIN                                                  Y/N 
          IF YES 1)  FLANK PAIN/ SUPRAPUBIC  
                       2)  RADIATION     Y/N 
 FEVER                                                                        Y/N 
         IF YES DESCRIBE 
 PYURIA                                                                 Y/N 
 RASH                                                                      Y/N 
 JAUNDICE                                                               Y/N 
 INSECT BITE/SNAKE BITE                                        Y/N 
 POISONING                                                              Y/N 
 NOCTURIA                                                               Y/N 
 URGENCY                                                                Y/N 
 FREQUENCY                                                            Y/N 
 HESITANCY                                                             Y/N 
 POLYURIA                                                               Y/N 
 BOWEL INCONTINENCE                                       Y/N 
 IMPOTENCE                                                           Y/N 
PAST HISTORY 
 DIABETES                                                                     Y/N 
 CAHD                                                                             Y/N 
 HYPERTENSION                                                          Y/N 
 PERIPHERAL VASCULAR DISEASE                        Y/N 
 CARDIAC FAILURE                                                    Y/N 
 LIVER FAILURE                                                          Y/N 
 RENL DISEASE                                                            Y/N 
 MAJOR SURGERY                                                       Y/N  
 UTI                                                                              Y/N 
 
PERSONAL HISTORY 
SMOKING                                                                     Y/N 
ALCOHOL                                                                     Y/N 
NSAIDS USE                                                                 Y/N 
DRUG ABUSE                                                               Y/N 
FAMILY HISTORY 
DIABETES                                                                     Y/N 
HYPERTENSION                                                           Y/N 
CAHD                                                                               Y/N 
RENAL DISEASE                                                            Y/N 
EXAMINATION 
CONCIOUSNESS                                    NORMAL/ALTERTED 
PALLOR                                                                           Y/N 
CYANOSIS                                                                       Y/N 
CLUBBING                                                                       Y/N 
PEDAL EDEMA                                                               Y/N 
FACIAL PUFFINESS                                                       Y/N 
 JVP                                                        NORMAL/ELEVATED 
TEMPRATURE 
 BLOOD PRESSURE 
 PULSE RATE  
 URINE OUTPUT 
CARDIOVASCULAR    SYSTEM 
 HEART SOUNDS                                                        
 MURMUR                                                                       Y/N 
 S3\S4\RUB                                                                      Y/N 
 RESPIRATORY SYSTEM 
  RALES                                                                            Y/N 
  PLEURAL EFFUSION                                                  Y/N 
 GASTERO INTERSTINAL SYSTEM 
  TENDERNESS                                                               Y/N 
   IF YES SPECIFY THE AREA: 
    FREE FLUID                                                                Y/N 
   ORGANOMEGALY                                                      Y/N 
      IF YES DESCRIBE: 
 CENTRAL NERVOUS SYSTEM 
   CONCIOUSNESS                                   NORMAL/ALTERED 
   ORIENTATION                                       NORMAL/ ALTERED 
   ASTERXIS                                                                      Y/N 
INVESTIGATIONS 
1) RENAL FUNCTION TESTS 
2) HEMOGRAM 
          HB                           : 
          TC                            :  
SUGAR       
UREA       
CREATININE       
SODIUM       
POTTASIUM       
BICARBONATE       
PH       
          DC                           : 
          ESR                         : 
           PLATELETS          : 
3) URINE 
           AIBUMIN              : 
           SUGAR                  : 
           DEPOSITS             : 
           RBCS                      : 
           CASTS                   : 
           HB                          : 
           SODIUM               : 
           CREATININE        : 
4) URINE PROTEIN 
 CREATININE RATIO    : 
5)  FE NA                    : 
6) ECG                          : 
7) CHEST X-RAY         : 
8) USG ABDOMEN      : 
9)  MSAT/MAT             : 
10) PERIPHERAL 
         SMEAR/QBC           :  
11) BLOOD C/S             : 
12) URINE C/S              :   
13)  LFT :  
FINAL DIAGNOSIS 
               RIFLE CRITERIA        RISK / INJURY / FAILURE              
               TYPE OF  AKI             PRERENAL/RENAL/ POSTRENAL  
               ETIOLOGY            
 COMPLICATIONS  
 TREATED : CONSERVATIVELY\HEMODIALYSIS/ PERITONEAL DIALYSIS 
 OUTCOME : RECOVERED\DIED 
 HOSPITAL ACQUIRED / COMMUNITY ACQUIRED 
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1 48 M 19937/07 1 1 2 2 1 2 2 2 2 2 140/90 1 2 1 1 2 2 2+
2 80 M 21228/07 1 2 1 1 2 1 2 2 1 2 160/80 2 2 1 1 2 2 3+
3 48 F 21919/07 1 1 1 1 1 2 2 2 2 1 100/70 1 2 1 2 1 2 2+ 0.29
4 25 M 19361/07 2 2 2 1 2 1 1 2 2 2 169/100 2 2 2 2 1 1 2+ 1.3
5 20 F 25813/07 1 2 2 1 2 1 1 2 2 1 140/100 2 2 2 1 1 2 1+
6 40 F 11221/07 1 2 1 1 2 2 2 2 2 2 110/70 2 2 1 1 2 2 3+
7 17 M 20241/07 2 1 2 2 2 2 2 2 2 2 130/80 1 1 2 1 2 2 2+ 0.6
8 20 F 28219/07 1 2 1 1 1 1 2 2 2 2 170/110 2 2 1 1 2 2 3+
9 27 F 11976/07 1 1 2 2 2 2 2 2 2 2 110/80 1 2 2 2 2 2 2+
10 60 M 19337/07 1 1 2 2 2 2 2 2 1 1 140/90 1 1 1 1 2 2 1+
11 29 M 22928/07 1 1 2 1 2 2 2 2 1 2 110/80 1 2 1 1 1 2 3+
12 17 F 27850/07 2 2 2 2 2 2 2 1 2 2 120/80 2 2 2 2 2 2 nil
13 36 M 22937/07 1 2 1 1 2 2 2 2 2 2 150/90 2 2 2 2 2 2 2+
14 17
F
21187/07 1 1 2 1 2 2 2 2 1 2 160/90 1 2 1 1 1 2 3+ 1.4
15 30 M 23621/07 1 2 1 1 2 2 2 2 2 2 130/80 2 2 2 2 2 2 3+
16 75 M 23418/07 1 2 1 2 2 1 2 2 2 2 150/100 2 2 2 2 2 2 3+
17 45 F 21136/07 1 2 1 2 1 1 2 2 1 2 120/70 2 2 1 2 2 2 2+ 0.4
18 18 M 22791/07 1 2 1 1 1 1 2 2 1 2 130/100 2 2 1 1 2 2 2+ 1.5
19 40 F 28437/07 1 1 2 1 1 1 2 2 2 1 130/70 1 2 1 1 1 2 3+
20 55 M 18189/07 1 2 2 2 2 1 2 2 2 2 156/80 2 2 2 2 2 2 1+
21 43 F 29919/07 1 2 1 1 1 2 2 2 2 1 180/90 2 2 1 1 2 2 2+ 0.5
22 13 M 21038/07 2 2 2 2 2 2 1 2 2 2 110/90 2 2 2 1 1 2 3+
23 60 M 23661/07 1 1 1 1 1 2 2 2 1 2 150/80 1 1 1 1 1 2 1+ 2
24 45 M 22932/07 1 2 1 1 2 2 2 2 2 2 140/80 2 2 2 2 2 2 3+
25 35 F 34098/07 1 1 1 1 2 2 2 2 2 2 130/90 1 2 1 2 2 1 3+
26 70 M 28199/07 1 2 2 2 2 2 2 1 2 2 140/70 2 2 2 2 2 2 1+_ 0.1
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27 17 M 36681/07 1 1 2 1 2 2 2 2 2 2 120/80 1 2 2 1 1 1 1+
28 60 M 22791/07 1 2 1 1 1 2 2 2 2 2 150/80 2 2 1 2 2 2 4+
29 75 M 30690/07 1 1 2 1 2 2 2 2 1 1 180/110 1 1 1 1 1 1 5+
30 33 F 31528/07 1 2 1 1 2 2 2 2 2 1 150/90 2 2 1 1 2 2 2+
31 20 M 22771/07 1 2 1 1 2 2 2 2 2 2 110/80 2 2 2 2 2 2 3+
32 55 F 25787/07 1 1 2 2 1 1 2 2 2 2 140/100 1 2 1 1 1 2 5+ 2.2
33 34 M 21268/07 1 2 1 1 2 2 2 2 2 2 130/100 2 2 2 2 2 2 3+
34 46 M 30326/07 1 1 2 1 2 2 2 2 2 2 50/? 1 2 2 1 1 1 2+ 1.4
35 65 F 39001/07 2 2 1 2 1 2 2 2 2 1 160/90 2 2 2 1 1 2 3+
36 55 F 30938/07 2 1 2 2 2 2 2 2 1 1 160/100 1 2 1 1 1 1 2+
37 35 F 35781/07 1 2 1 1 1 2 2 2 2 2 140/90 2 2 1 1 2 2 1+
38 26 M 28167/07 1 1 2 2 2 2 2 2 2 2 110/80 1 2 1 1 2 2 3+
39 40 F 34970/07 1 1 2 2 1 1 2 2 2 2 120/80 1 2 1 1 2 2 1+ 0.6
40 46 M 24725/07 1 2 2 2 2 1 1 2 2 2 150/70 2 2 1 2 2 2 3+ 0.3
41 25 F 39735/07 1 2 1 1 1 2 2 2 2 2 120/80 2 2 2 1 2 2 3+
42 66 M 35776/07 1 2 1 1 2 1 2 2 2 1 150/90 2 2 1 1 2 2 2+
43 40 F 32789/07 1 2 1 1 1 1 2 2 2 2 110/90 2 2 1 1 2 2 2+
44 20 M 24584/07 1 2 2 2 1 2 2 2 2 2 140/80 2 2 1 1 1 2 2+
45 21 M 25523/07 2 2 1 1 2 1 2 2 2 2 120/100 2 2 2 1 2 2 1+
46 23 F 30616/07 1 1 2 1 2 2 2 2 2 2 130/80 1 2 2 2 2 2 2+
47 19 M 22801/07 1 2 1 2 2 2 2 2 2 2 160/80 2 2 2 2 2 2 2+
48 85 F 11108/07 1 1 2 2 2 2 2 2 1 2 60/? 1 2 1 1 1 1 3+
49 23 M 29813/07 1 2 2 1 2 1 1 2 2 2 150/70 2 2 2 2 2 2 5+ 0.7
50 60 M 39753/07 1 2 1 1 2 1 2 2 2 2 140/90 2 2 2 2 2 2 1+
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51 17 F 35509/07 1 2 1 1 2 1 2 2 2 2 100/60 1 2 2 2 2 2 2+
52 30 M 39644/07 1 1 2 2 2 1 2 2 1 2 150/80 1 2 2 1 2 2 1+
53 41 F 36918/07 1 2 1 1 2 1 2 2 2 2 140/100 2 2 2 2 2 2 4+
54 17 F 34080/07 1 1 2 1 1 1 2 2 2 1 180/100 1 2 2 2 2 2 4
55 76 F 39185/07 1 2 1 2 2 2 2 2 2 2 140/80 2 2 2 1 2 2 1+
56 24 M 39741/07 2 2 2 1 2 1 1 2 2 2 130/80 2 2 2 2 2 2 3+
57 60 M 39692/07 1 1 2 1 2 2 2 2 1 2 140/100 1 2 1 1 1 1 2+
58 46 M 2865/08 1 1 1 1 2 2 2 2 2 2 100/70 1 2 2 2 2 2 1+
59 51 F 25571/08 1 2 1 1 2 1 2 2 2 2 120/70 2 2 1 1 2 2 3+
60 43 M 36585/07 1 1 2 1 2 2 2 2 2 2 150/80 1 1 2 1 2 2 1+
61 45 M 2926/08 1 2 1 1 2 2 2 2 2 2 140/70 2 2 2 1 2 2 4+
62 50 M 2932/08 1 1 2 1 2 2 2 2 2 2 136/70 1 2 1 1 2 2 3+
63 48 M 43125/07 1 1 2 1 2 1 2 2 2 2 140/100 1 1 1 1 2 2 3+
64 13 M 3819/08 2 1 1 1 2 2 2 2 2 2 130/100 2 2 1 1 2 2 4+
65 54 M 1781/08 1 2 1 2 1 2 2 2 2 2 150/90 2 2 2 2 2 2 2+
66 39 F 8070/08 1 1 2 2 2 1 1 1 2 2 170/100 1 2 1 1 1 2 4+ 2.2
67 45 M 6306/08 1 2 1 1 2 1 2 2 2 2 130/70 2 2 2 1 2 2 1+
68 46 F 4676/08 1 1 2 2 2 2 2 1 1 2 160/80 1 2 2 2 1 1 2+
69 58 M 9772/08 1 2 1 1 2 1 2 2 2 2 110/80 1 2 1 2 2 2 2+
70 75 M 11547/08 1 1 2 1 2 2 2 2 2 2 110/60 1 1 1 2 2 2 3+ 0.5
71 35 M 9775/08 1 2 1 1 1 1 2 2 2 2 140/100 2 2 1 1 2 2 2+
72 26 M 5509/08 1 1 2 1 2 2 2 2 2 2 120/60 2 1 2 1 1 1 2+
73 48 M 11390/08 1 1 1 1 1 1 2 2 2 2 140/70 2 2 1 1 2 1 1+
74 30 M 9776/08 1 1 1 1 2 2 2 2 2 2 100/70 1 1 2 1 2 2 3+
75 15 F 12660/08 1 2 1 1 2 1 2 2 2 2 110/80 2 2 2 1 2 2 3+
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76 30 F 5474/08 1 1 2 2 2 2 2 2 2 2 150/110 1 2 2 2 2 2 1+
77 20 F 12283/08 1 2 1 2 2 2 2 2 2 2 140/70 2 2 2 2 2 2 2+
78 36 M 10189/08 1 2 1 2 2 2 2 2 2 2 160/90 2 2 2 2 2 2 2+
79 55 M 7922/08 1 1 2 1 1 1 2 2 1 2 160/110 2 2 2 2 2 2 4+ 1.5
80 55 F 20410/08 1 2 1 2 2 1 2 2 2 2 100/60 2 2 2 2 2 2 2+
81 55 M 22117/08 1 1 2 1 2 1 2 2 1 2 150/80 1 1 1 1 2 2 4+
82 48 F 24139/08 2 2 2 2 2 2 2 2 2 2 150/80 2 2 2 2 2 2 2+
83 76 M 38243/08 1 1 1 1 1 1 2 2 1 2 160/90 1 2 1 1 1 1 3+
84 75 F 34497/08 1 2 1 1 1 1 2 2 1 1 160/110 2 2 1 1 2 2 1+
85 28 M 34653/08 2 2 2 2 2 2 2 2 2 1 160/100 2 2 2 2 2 2 nil 0.3
86 30 M 35401/08 1 2 2 1 2 1 1 2 1 2 130/70 2 2 2 2 2 2 3+ 0.6
87 60 F 37440/08 1 2 1 1 2 2 2 2 2 2 140/80 1 2 1 2 2 2 2+
88 13 F 37776/08 1 1 2 1 1 2 2 2 2 2 160/100 1 2 1 1 2 2 5+ 2.6
89 65 M 45376/08 1 2 1 2 2 1 2 2 2 2 120/80 2 2 2 2 2 2 2+
90 50 M 39900/08 1 1 1 1 2 1 2 2 2 2 130/100 1 1 1 2 2 2 3+ 0.7
91 55 F 20395/08 1 1 1 1 2 1 2 2 2 2 140/90 1 2 1 2 2 2 1+
92 22 F 41828/08 1 2 2 2 1 1 2 2 2 2 130/80 1 2 2 2 2 2 4+
93 26 F 70102/08 1 1 2 1 1 2 2 2 2 2 110/70 1 2 1 1 2 2 5+ 2
94 50 M 69250/08 1 1 2 1 2 1 2 2 2 2 130/100 1 2 2 2 2 2 1+
95 70 M 39084/08 1 2 1 2 2 1 2 2 2 2 160/100 2 2 2 2 2 2 2+
96 50 F 66653/08 1 1 1 2 1 1 2 2 1 2 140/90 1 2 1 1 1 1 3+
97 64 M 39878/08 1 2 1 2 2 2 2 2 2 2 140/70 2 2 2 2 2 2 3+
98 52 F 19449/08 2 2 2 2 2 2 2 1 2 2 130/70 2 2 2 2 2 2 2+
99 30 F 41706/08 1 2 2 1 2 1 1 2 2 2 150/80 1 2 2 2 2 2 1+
100 22 F 42426/08 1 1 2 1 2 1 2 2 2 2 160/90 2 2 1 1 2 2 3+ 3.1
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I
F
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E
first max final
9.8 1 4500 2.6 1 1 2 56 1.8 1.8 1 134 4.5 1 R
10.8 2 6400 1.2 2 2 2 78 1.6 2 0.8 123 3.5 stool-e.coli+ 1 R
10 3 6700 3.4 2 2 2 108 1.5 1.8 1.1 145 3.9 1 R
1.3 5.9 4 11000 1.2 2 2 2 112 3.2 9.8 6.4 129 3 ABG- met.acidosis 2 F
0.9 8.6 5 8900 2.2 2 2 2 76 2.2 2.8 0.6 156 4.9 ABG- met.acidosis 2 I
10.8 6 7000 2.6 2 2 2 88 1.2 2.8 1 145 3.6 1 I
9.2 7 4800 2 1 2 2 70 1.8 1.8 1 138 4.2 1 R
12 8 7300 3.1 2 2 2 67 2.5 3 1.4 134 2.8 STOOL-EH+ 1 I
9.7 9 9600 2.8 1 2 2 68 1.5 1.8 0.9 135 3.7 1 R
0.6 9 10 5600 1.8 2 1 2 98 2 2 1 138 3.8 USG-N 1 R
8.8 11 3200 1.6 2 2 2 67 1.1 5.6 9.2 156 2.2 ABG-met.acidosis urine c&s- E.coli+ 2 F
10 12 7300 0.9 2 2 2 52 2.3 2.8 1.2 146 5.6 2 I
10.8 13 6000 1.2 2 2 2 102 1.8 2.1 1.3 134 3.4 stool-e.coli+ 1 I
1.5 7.9 14 13000 0.5 2 2 2 45 0.8 4.5 1.4 148 4.2
CXR-rt lower lobe 
pneumonia USG-N 2 F
0.4 11.9 15 5100 2.3 2 2 2 96 3.2 4 1.1 138 5.2 1 F
6.7 16 4100 3.6 2 2 2 67 2.8 3.4 3.4 110 6.8 2 I
12.3 17 4800 3.6 2 2 2 92 6.7 8.9 6.8 138 6.7 2 F
10.2 18 8700 4.1 2 2 2 83 1.5 1.8 1 135 4.4 stool- e.coli+ 1 R
9.4 19 5100 2.3 2 1 1 120 2.3 2.8 1.1 156 4 USG-N 1 I
8.6 20 7300 2 2 2 2 82 6.2 7.8 1.6 130 5.6 USG-BPH 3 F
10 21 9000 1.3 2 2 2 96 3 5.6 1.2 148 4.8 USG-N 1 F
13 22 6900 3.2 2 2 2 56 1.1 2 1 130 3 1 R
1.5 9.9 23 14500 0.95 2 2 2 81 1 4.7 4.4 136 4.3 USG-N 2 F
11.6 24 7700 1.8 2 2 2 94 1.6 1.6 0.9 135 4.5 1 R
12 25 6500 3.2 2 1 2 62 2.2 2.8 1.1 134 3.8 1 I
1 10 26 9500 0.8 2 2 2 78 0.8 1.6 0.9 140 5 CT-20 MIN 2 R
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9.2 27 5000 3.4 1 2 2 60 4.2 8.3 1.4 142 4.7 ABG- resp.alkalosis 2 F
1.2 10.4 28 10100 2.2 2 2 2 80 5.2 8.3 1.1 152 2.5 stool- giardia+ USG-N 2 I
2 8.6 29 4200 1.4 2 2 2 58 3.2 9.2 9.2 156 5.3 USG-N 2 F
9.6 30 5800 1.8 2 2 2 108 1 1.6 0.8 143 4.8 1 R
11.8 31 4600 2.2 2 2 2 114 6.2 8.6 1.3 148 3.4 stool occult bld+ 2 F
8.8 32 9300 1 2 2 2 54 2.4 2.8 1.3 128 3.4 USG-N 2 I
10 33 4000 3.8 2 2 2 82 1.6 1.6 0.6 138 5.7 1 R
1.4 9.6 34 9600 1.2 1 2 2 67 4.5 7.8 5.6 140 4.5 2 F
9.8 35 4800 3.2 2 2 2 98 1.5 1.8 1 138 5.6 1 R
12.5 36 12100 4 2 2 2 68 1 6.6 6 146 3.7 BLD C&S- staph+ ABG-met.acidosis 2 F
10 37 5800 3.5 2 2 2 94 1 2.5 1 142 3.5 1 I
12 38 8300 2.8 1 1 2 84 1.2 1.7 0.6 127 4.1 1 R
0.8 9 39 4300 2.3 2 2 1 98 3.4 4.6 1.1 132 4.3 USG-N 1 F
1 11.2 40 5000 1.9 2 2 2 45 1.8 2.3 1 138 2.8 USG-N 2 I
0.2 8.9 41 7200 1.5 2 2 2 98 3.4 4.5 1.2 126 3.8 1 R
11.9 42 5900 3 2 2 2 86 1.4 1.6 0.7 150 3.4 STOOL- e.coli+ 1 R
9.8 43 9100 2.7 2 2 2 56 1.8 1.8 1.1 132 4.9 1 R
1.4 10 44 4300 1 2 2 2 48 2.3 3.4 1.2 134 4.5 CT-15 MIN 2 F
11 45 7300 2 2 2 2 97 1.2 1.8 0.8 143 3.8 1 R
9 46 6800 1.7 1 2 1 56 1.8 1.8 0.7 134 3.5 1 R
10.3 47 7900 3.2 2 2 2 50 1.4 1.6 1 142 5.4 1 I
9 48 9900 1 2 2 2 78 0.7 7.8 8 123 6 BLD C&S- e.coli+ 2 F
1 12.7 49 4500 2.3 2 2 2 67 3.2 8.9 1.2 150 3.8 2 F
9.2 50 5900 2.3 2 2 2 50 0.7 1.4 0.7 138 4.1 stool-enterobius vermicularis+ 1 R
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12.8 51 8700 3.7 2 2 2 68 1.5 1.5 0.8 144 5.6 1 R
10.3 52 10200 2.6 1 1 2 89 1.4 2 0.6 148 3.4 USG-N 1 R
11 53 6000 1.3 2 2 2 80 5 8.2 1.2 152 6.7 1 F
8.4 54 3700 0.9 2 1 2 100 1 1.9 1 138 4.3 USG-N 1 R
12.4 55 6300 1.8 2 2 2 98 1.8 1.8 1.1 134 4.7 stool-e.coli+ 1 R
1.2 9.5 56 5200 2.8 2 2 2 68 1.4 2.2 0.6 140 3.4 1 I
10.5 57 9200 4.2 2 2 2 134 0.9 8.2 4.2 130 4.2 1 F
12 58 6700 3.8 2 2 2 96 1.8 1.8 0.7 128 4.8 stool-giardia+ 1 R
9.2 59 10000 2.6 2 2 2 73 1.4 1.9 0.8 146 5.2 stool-giardia+ 1 R
10 60 6400 1.1 1 2 2 93 2.8 2.8 1.3 152 3.4 1 I
12.4 61 4500 2.7 2 2 2 106 1.4 1.7 1 138 5.8 1 R
11.6 62 5600 3.6 2 2 1 58 1.5 1.8 1 127 4 1 R
0.2 7.2 63 9200 1.3 1 1 2 82 1.3 1.9 0.6 150 3.2 1 R
11.8 64 5800 1.8 2 2 2 48 1.4 1.7 0.9 148 2.2 1 F
10.5 65 3900 3.8 2 2 2 84 1.8 1.8 1.1 134 5 stool-EH+ 1 R
1 10.8 66 9700 1.1 2 2 2 45 1.6 2.4 0.9 146 4.6 2 I
11.7 67 8400 1.4 2 2 2 54 1.6 1.6 0.8 144 4.8 1 R
1.6 9.4 68 6000 0.95 2 2 2 1.8 1.8 5.6 1.2 136 4.5 USG-N 2 F
13.6 69 4800 4.6 2 2 2 78 2.3 2.8 0.9 130 4 stool-e.coli+ 1 I
0.6 11 70 1100001.4 1 1 2 72 1.3 1.5 1 146 3.5 1 R
10.8 71 6300 3.6 2 2 2 104 1.7 1.7 0.9 152 4.7 1 R
9.2 72 4100 1 1 2 2 72 3.9 4.5 2.2 140 7.2 2 F
10.2 73 5000 3.9 2 2 2 102 1.8 1.8 1 154 4.2 CSF-sugar-20 mg, protein- 146 mg 1 R
9.6 74 8200 3.1 1 1 2 86 1.5 1.9 0.9 137 5 2 R
9 75 7600 2.3 2 2 2 84 2.1 2.5 0.8 142 3.2 STOOL-EH+ 1 I
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8 76 5200 3.8 1 2 2 75 2 2.5 1.5 156 4.8 1 I
9.8 77 4800 2 2 2 2 67 1.6 1.6 1 130 4.8 1 R
11.2 78 6900 2 2 2 2 48 1.5 1.9 1 135 2.6 1 R
1.2 9.4 79 3100 1.3 2 2 2 72 0.8 6.7 3.4 148 4.5 urine c&s- e.coli+ ABG-met.acidosis 2 F
10 80 5800 3.3 2 2 2 88 1.7 1.7 0.8 139 3.4 1 R
11.6 81 6800 3.7 2 1 2 96 1.8 1.8 0.8 144 4.6 USG-N 1 R
1 10.4 82 5700 2 2 2 2 69 0.8 2.8 0.9 156 4.3 USG-N RF+ 2 I
1.5 10.2 83 13600 2.3 2 2 2 70 0.7 4.3 1 149 4.5 sputum c&s- klebsella+ 2 F
11.2 84 8900 2.5 2 2 2 98 1.5 1.5 0.6 130 5.3 USG-N 1 R
10 85 8300 3.5 2 2 2 26 1 1.7 1 134 5.3 USG-N 1 R
0.7 10 86 7000 4.2 2 2 2 56 1.5 2.6 1.2 140 3.7 USG-N 1 I
11 87 7800 3 2 2 2 110 1.6 1.8 0.7 128 3.1 1 R
1.3 9.2 88 9000 3.2 2 2 2 49 2 2.9 1.2 146 3.5 USG-N 2 I
8.5 89 6200 2.2 2 2 2 90 1.4 1.8 0.8 155 4.8 1 R
1.1 9 90 9400 0.5 1 1 2 78 1.7 1.7 1 145 2.8 2 R
7.8 91 3400 0.8 1 2 2 66 3 9.7 4.9 129 4.9 ABG-metabolic acidosis 1 F
11 92 6700 3.1 2 2 2 107 1.6 2.3 1 127 3 stool- giardia+ 1 I
10.3 93 4500 2.1 2 2 2 68 2.5 2.9 1.3 142 5.6 USG-N 2 I
8.4 94 8400 2 2 2 2 74 2.2 2.2 1.8 129 3.1 USG- b/l staghorn calculi 3 I
8.9 95 7800 1 2 2 2 100 1.6 1.6 0.8 149 4.2 1 R
10 96 3800 1 2 2 2 64 4.5 7.4 7 125 2.9 BLD C&S- strepo. Viridans 2 F
10.6 97 7300 2 2 2 2 109 1.6 1.9 0.7 138 4.8 STOOL-EH+ 1 R
9.6 98 12000 0.8 2 2 2 71 3.4 5.4 2.3 142 6.4 CT- >15 min 2 F
1.2 11.4 99 6000 3.6 2 2 2 60 1.8 4.5 1 152 4.3 ABG-met. Acidosis 2 F
11.4 100 6500 1 2 2 2 67 1.6 2.1 0.8 136 3.4 2 I
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1 LEPTOSPIROSIS/MALARIA
2 ADD
3 ADD
4 metebolic acidosis UNKNOWN POISON 2
5 metebolic acidosis CUSO4 POISON
6 ADD
7 MALARIA
8 pulmonary edema ADD
9 MALARIA
10 LEPTOSPIROSIS
11 metebolic acidosis SEVERE SEPSIS 2
12 SNAKE BITE
13 ADD
14 SEVERE SEPSIS
15 ADD
16 arrythmias ADD
17 arrythmias ADD 2
18 ADD
19 pulmonary edema LEPTOSPIROSIS/ENTERIC FEVER
20 BPH
21 ADD
22 UNKNOWN POISON
23 hypotension SEPSIS/ SHOCK 1
24 ADD
25 ALTERED MENTAL STATUS LEPTOSPIROSIS
26 SNAKE BITE
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27 CEREBRAL MALARIA
28 pulmonary edema ADD
29 SEPSIS/ MODS 4
30 ADD
31 GI HEMORRHAGE ADD
32 NEPHRITIC SYNDROME(PIGN)
33 ADD
34 hypotension ALGID MALARIA 1
35 ADD
36 metebolic acidosis SEPSIS/ MODS 3
37 ADD
38 LEPTOSPIROSIS/MALARIA
39 ENTERIC FEVER
40 CUSO4 POISON
41 ADD
42 ADD
43 ADD
44
ALTERED MENTAL 
STATUS
SNAKE BITE
2
45 ADD
46 MALARIA/ ENTERIC FEVER
47 ADD
48 hypotension hyponatremiaSEPSIS/SHOCK 2
49 PARACETAMOL POISONING
50 ADD
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51 ADD
52 LEPTOSPIROSIS/MALARIA
53 hyperkalemia ADD
54 LEPTOSPIROSIS
55 ADD
56 CUSO4 POISON
57 pulmonary edema SEVERE SEPSIS 2
58 ADD
59 ADD
60 MALARIA
61 ADD
62 ENTERIC FEVER
63 LEPTOSPIROSIS/MALARIA
64 hypokalemia ADD
65 ADD
66 NEPHRITIC SYNDROME
67 ADD
68 SNAKE BITE
69 ADD
70 LEPTOSPIROSIS/MALARIA
71 ADD
72 arrythmias CEREBRAL MALARIA 2
73 TB MENINGITIS
74 MALARIA/ LEPTOSPIROSIS
75 ADD
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76 MALARIA
77 ADD
78 ADD
79 metebolic acidosis SEPSIS/MODS 4
80 ADD
81 LEPTOSPIROSIS
82 DRUG INDUCED (NSAIDS)
83 hiccups SEVERE SEPSIS
84 ADD
85 DRUG INDUCED (ACEI)
86 metebolic acidosis DICHROMATE POISONING 2
87 ADD
88 NEPHRITIC SYNDROME(PIGN)
89 ADD
90 MALARIA/ LEPTOSPIROSIS
91 metebolic acidosis MALARIA
92 ADD
93 NEPHRITIC SYNDROME
94 RENAL CALCULUS
95 ADD
96 hypotension SEPSIS/ SHOCK
97 ADD
98 arrythmias hyperkalemiaSNAKE BITE
99 metebolic acidosis DICHROMATE POISONING
100 NEPHROTIC SYNDROME
                                 ABBREVIATIONS-MASTER CHART 
s. no – serial number 
Ip.no –  In patient number 
PCR- Protein creatnine ratio 
 FENa- Fractional excretion of sodium 
MP-  Smear for malarial parasite 
MSAT- Macroscopic slide agglutination test 
ABG- Arterial blood gas analysis 
USG-N- Ultrasonogram  of  kidney  was normal study 
CT- Clotting time 
C&S – Culture and sensitivity 
CXR-Chest X-ray PA view 
ADD- Acute diarrhoeal disease 
CSF- Cerebrospinal fluid 
EH- Entamoeba histolytica 
Others- Other  investigations 
Oliguria- Hypertension 
    1- yes 
     2-no 
Fever-Alterde sensorium 
    1- yes 
    2-no 
MP, MSAT, WIDAL 
   1- Positive 
    2- Negative 
Type of AKI 
   1- Prerenal 
   2- Renal 
   3-Postrenal 
RIFLE 
   1- RISK 
   2-INJURY 
   3-FAILURE 
Treatment 
   1-Conservative 
   2-Peritoneal dialysis 
   3-Hemodialysis 
